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Proteomes of even well characterized 
organisms still contain a high percentage of 
proteins with unknown or uncertain 
molecular and/or biological function. A 
significant fraction of those proteins are 
predicted to have catalytic properties. Here 
we aimed at identifying the function of the 
Saccharomyces cerevisiae Ydr109c protein 
and of its human homolog FGGY, both of 
which belong to the broadly conserved FGGY 
family of carbohydrate kinases. Functionally 
identified members of this family 
phosphorylate 3- to 7-carbon sugars or sugar 
derivatives, but the endogenous substrate of 
S. cerevisiae Ydr109c and human FGGY has 
remained unknown. Untargeted 
metabolomics analysis of an S. cerevisiae 
deletion mutant of YDR109C revealed 
ribulose as one of the metabolites with the 
most significantly changed intracellular 
concentration as compared to a wild-type 
strain. In human HEK293 cells, ribulose 
could only be detected when ribitol was added 
to the cultivation medium and under this 
condition, FGGY silencing led to ribulose 
accumulation. Biochemical characterization 
of the recombinant purified Ydr109c and 
FGGY proteins showed a clear substrate 
preference of both kinases for D-ribulose over 
a range of other sugars and sugar derivatives 
tested, including L-ribulose. Detailed 
sequence and structural analyses of Ydr109c 
and FGGY as well as homologs thereof 
furthermore allowed the definition of a 5-
residue D-ribulokinase signature motif 
(TCSLV). The physiological role of the herein 
identified eukaryotic D-ribulokinase remains 
unclear, but we speculate that S. cerevisiae 
Ydr109c and human FGGY could act as 
metabolite repair enzymes, serving to re-
phosphorylate free D-ribulose generated by 
promiscuous phosphatases from D-ribulose-5-
phosphate. In human cells, FGGY can 
additionally participate in ribitol metabolism. 
 
A major challenge in the post-genomic 
era is that a large fraction of protein-coding 
genes remain functionally unknown or poorly 
characterized in all sequenced genomes (1,2). 
Even in a well characterized organism such as S. 
cerevisiae, the number of protein-coding genes 
with no known biological function, based on 
database searches in UniProt, amounts to 
approximately 30%, which corresponds to about 
2000 proteins. In this study, we investigated the 
function of two proteins of unknown function, 
the S. cerevisiae Ydr109c protein (Q04585) and 
its human homolog FGGY (Q96C11). Both 
proteins contain the highly conserved FGGY_N 
and FGGY_C Pfam domains. The members of 
the FGGY family of carbohydrate kinases, of 
which more than 8000 sequences are known 
according to the Pfam database, are widespread 
across the various kingdoms of life and show a 
high functional diversification (3). They 
phosphorylate C3 to C7 sugars or sugar 
derivatives and a divergent subfamily of the 
FGGY protein family is involved in quorum 
sensing by phosphorylating the signaling 
molecule autoinducer-2 (AI-2, a furanosyl borate 
diester) (3). There are seven Swiss-Prot 
reviewed FGGY domain containing proteins 
encoded by the human genome: 
Sedoheptulokinase (Q9UHJ6), Xylulose kinase 
(O75191), Glycerol kinase (P32189), Glycerol 
kinase 2 (Q14410), Putative glycerol kinase 3 
(Q14409), Putative glycerol kinase 5 (Q6ZS86), 
and FGGY carbohydrate kinase domain-
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containing protein (Q96C11; designated 
hereafter ‘FGGY’). The S. cerevisiae genome 
encodes four Swiss-Prot reviewed FGGY 
domain containing proteins: Xylulose kinase 
(P42826), Glycerol kinase (P32190), Mpa43 
(P53583), and Ydr109c (Q04585). The 
motivation behind this study was the existence 
of a functionally uncharacterized carbohydrate 
kinase (Ydr109c) in S. cerevisiae with a 
homologous protein in humans (FGGY), which 
has been linked to S-ALS1 and bipolar disorder. 
The first study reporting an FGGY 
association to S-ALS was by Dunckley et al. (4). 
Performing a genome-wide association study 
comparing healthy controls and S-ALS patients 
of European Caucasian descent living in the 
USA, the authors reported 10 statistically 
significant SNPs associated to S-ALS. The most 
significant gene associated to S-ALS was FGGY 
(FLJ10986). Assessment of FGGY expression in 
the same study using Western blotting indicated 
the presence of FGGY protein in cerebrospinal 
fluid, spinal cord, small intestine, lung, kidney, 
liver, and fetal brain. Association of the FGGY 
gene with S-ALS could, however, not be 
confirmed in subsequent studies using different 
cohorts (5-9). The contradictory results on the 
involvement of FGGY in S-ALS were suggested 
to be due to the variable causes and complexity 
of the disease itself (10). An exome sequencing 
study in a family with three female patients 
affected by bipolar disorder and one unaffected 
male sibling identified heterozygous, very rare, 
and likely protein-damaging variants in eight 
brain-expressed genes, including FGGY (11). 
These variants were shared by the three affected 
siblings, but not present in the unaffected sibling 
and more than 200 controls. Replication and 
functional studies would, however, be required 
to confirm disease association and test causality, 
respectively, of the identified variants. Although 
these observations suggest a possible link of the 
FGGY gene with neurodegenerative or 
psychiatric disorders, the overall evidence 
supporting this link remains thus limited at this 
stage. 
In recent years, metabolomics has 
emerged as a new tool for enzyme function 
discovery. Untargeted metabolomics has enabled 
us to analyze metabolites in biological samples 
in a much more comprehensive way and is a 
powerful technique for hypothesis generation. A 
remaining challenge of this methodology is 
metabolite identification: the data obtained via 
untargeted metabolomics contains thousands of 
metabolite features, with relatively few being 
identified in the end (12). In contrast to 
untargeted metabolomics, targeted metabolomics 
serves to identify and/or quantify a more or less 
limited set of preselected metabolites. In the 
field of enzymology, metabolomics or 
metabolite profiling techniques may be exploited 
to identify endogenous enzyme substrates. 
Ewald et al. studied the effect of single 
enzymatic gene deletions in central carbon 
metabolism and of environmental changes on the 
metabolome of S. cerevisiae (13). 30-40% of the 
enzymatic gene deletions tested led to a very 
local metabolic response in proximity of the 
enzyme deficiency (often accumulation of the 
substrate of the deleted enzyme) (13). The 
observations suggest that this approach is a 
viable strategy for enzyme function 
identifications through comparative 
metabolomics analyses of wild-type cells and 
cells deficient in metabolic enzymes of unknown 
function. A notable advantage of this type of 
approach over in vitro substrate screens with 
purified enzymes is the higher likelihood of 
identifying the true physiological or endogenous 
substrate(s) of the deleted enzyme under 
investigation (14). Two recent examples of 
enzyme identifications in connection with the 
pentose phosphate pathway and using LC-MS 
based metabolite profiling in samples derived 
from enzyme-deficient organisms are yeast 
sedoheptulose-1,7-bisphosphatase (SHB17) (15) 
and mammalian sedoheptulokinase (SHPK) 
(16).  
LC-MS-based metabolite profiling can 
involve full scan or tandem MS methods. In the 
full scan MS methods, only the m/z of parent 
ions and/or adducts of the parent ions are 
utilized along with the retention time 
characteristic of each molecule to identify 
detected metabolites. Tandem MS methods 
increase the potential for metabolite 
identification by allowing the generation of m/z 
fingerprints (MS2 spectra), obtained by 
fragmenting the parent ions, that can then be 
matched with those of metabolite standards. We 
used a combination of untargeted full scan MS, 
ddMS2 and targeted methods to search for the 
endogenous substrate of the S. cerevisiae 
Ydr109c protein using ydr109cΔ knockout 
strains. We found that ribulose was one of the 
most significantly changed metabolites, 
accumulating in the ydr109cΔ mutants as 
compared to the wild-type control strains. D-
Ribulose was subsequently shown to be the 
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preferred substrate of the yeast Ydr109c kinase 
as well as for its human homolog FGGY in vitro. 
In contrast to yeast cells, ribulose formation in 
human HEK293 cells could only be detected 
when ribitol was supplemented to the cultivation 
medium. Under this condition, FGGY 
knockdown led to ribulose accumulation in the 
HEK293 cells. Taken together, our results 
establish the molecular identity of D-
ribulokinase in yeast and humans. Furthermore, 
combined sequence and structural analyses 
furthermore allowed us to identify a conserved 
signature motif that enables the prediction of D-
ribulokinase activity with high confidence for 
FGGY protein family members. 
 
RESULTS 
YDR109C gene deletion leads to 
ribulose accumulation in different S. cerevisiae 
strains–The YDR109C gene is currently 
annotated as an uncharacterized open reading 
frame in the Saccharomyces genome database 
(SGD), which means, according to the SGD 
glossary, that ‘there are no specific experimental 
data demonstrating that a gene product is 
produced in S. cerevisiae’. In addition, no 
molecular or biological function has been 
assigned to this gene yet. Therefore, we started 
by investigating YDR109C expression in our 
prototrophic WT strain by quantitative RT-PCR. 
The YDR109C transcript was readily detected in 
exponentially growing wild-type cells (Fig. 1), 
with an average measured Ct value of 26.3 ± 0.3 
(mean ± SD; n = 3) as compared to an average 
measured Ct value of 23.8 ± 0.5 (mean ± SD; n 
= 3) for the mannosyltransferase ALG9, which is 
commonly used as a reference gene for 
quantitative RT-PCR studies in S. cerevisiae 
(17). The YDR109C transcript was not 
detectable in our ydr109cΔ prototrophic 
knockout strain (Fig. 1). These results show that 
YDR109C is transcribed in S. cerevisiae and 
indicate that our knockout strain is a good model 
to explore the function of this gene. The 
Ydr109c protein was also detected and 
quantified (119 molecules/cell) in a proteomics 
study (18). 
The Ydr109c protein sequence contains 
the widely conserved Pfam FGGY_N and 
FGGY_C domains, suggesting that it functions, 
as other members of the FGGY protein 
superfamily, as a kinase acting on sugars or 
sugar derivatives. To identify endogenous 
substrate candidates of this putative sugar 
kinase, we analyzed the polar metabolites 
extracted from our prototrophic WT and 
ydr109cΔ strains using LC-HRMS. Two 
complementary methods, ZIC-HILIC coupled to 
ddMS2 and reverse phase (RP) chromatography 
coupled to full scan MS with polarity switching, 
were used. Ribulose was found to be the 
metabolite with the highest -fold change (more 
than 30-fold increase in KO vs. WT), among the 
ones confirmed to be produced endogenously by 
the below-described co-cultivation method, 
using the ZIC-HILIC-ddMS2 method in 
negative ionization mode (Fig. 2A and Table 
S1). We repeated the same analysis in metabolite 
extracts derived from a ydr109cΔ deletion strain 
in the auxotrophic background BY4741 and the 
corresponding WT strain. As for the 
prototrophic strains, ribulose was identified as 
the most significantly changed metabolite, 
accumulating in the auxotrophic ydr109cΔ 
mutant, among the metabolites detected in 
negative mode (23-fold increase in KO vs. WT; 
Table S2). Identification of the accumulating 
compound as ribulose was based on accurate 
mass (m/z 149.0445), co-elution with a D-
ribulose standard (Fig. 2A), and MS2 
fragmentation pattern (Fig. 2B). Polar 
metabolites were separated better using ZIC-
HILIC chromatography; the bulk of yeast polar 
metabolites eluted very early with our reverse 
phase chromatography method and was 
therefore not used for further experiments in this 
study. Using the ZIC-HILIC-based method, we 
were able to separate ribulose from other 
pentoses (Fig. 2C). We were, however, not able 
to separate the D and L forms of ribulose. 
Although we could detect a number of other 
sugars and sugar derivatives including glucose, 
arabinose, mannitol, ribitol, maltose, xylose, 
galactose, 2-deoxyribose (identification based on 
accurate mass and co-elution with standards) in 
the analyzed yeast metabolite extracts, only 
ribitol showed significantly different levels (> 2-
fold higher in the prototrophic and auxotrophic 
KO strains than in the corresponding WT 
strains; Table S1, S2, S3, and S4) upon 
YDR109C deletion in addition to ribulose. Taken 
together, these analyses highlighted ribulose as a 
strong endogenous substrate candidate for the 
putative Ydr109c kinase.  
Free ribulose has not been described so 
far as an endogenous metabolite in S. cerevisiae 
and there is also no entry for ribulose in the 
YMDB (19). Our detection of ribulose 
accumulation in yeast strains grown on minimal 
controlled medium containing D-glucose as the 
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sole carbon source suggested that yeast cells can 
form free ribulose from D-glucose. We wanted 
to consolidate this observation via stable isotope 
labeling (SIL) experiments in which we replaced 
the non-labeled glucose with U-13C-D-glucose in 
an otherwise identical cultivation medium. In 
these experiments, we observed a + 5 m/z	 shift 
for the pentose peak (monoisotopic mass of 
154.0612) accumulating in the ydr109cΔ mutant 
and perfectly co-eluting with a spiked-in 12C-D-
ribulose standard (Fig. 2D). As can also be seen 
in Fig. 2D, spiked-in non-labeled D-xylulose and 
D-ribose standards, which elute in close 
proximity to the D-ribulose standard (see Fig. 
2C), eluted slightly later than the labeled pentose 
accumulating in the ydr109cΔ mutant. These 
results consolidate the identity of the compound 
building up after deletion of the YDR109C gene 
as ribulose and show that S. cerevisiae can 
produce this compound from D-glucose. Using a 
13C internal standard isotope dilution MS 
method and biovolume measurement by Coulter 
counter, we estimated an intracellular ribulose 
concentration of 0.054 ± 0.010 mM and 2.2 ± 
0.3 mM (means ± SD; n = 6) for the prototrophic 
WT and ydr109cΔ strains, respectively. 
Effect of YDR109C deletion on 
metabolite levels other than ribulose and ribitol–
The ZIC-HILIC-ddMS2 data obtained with the 
prototrophic strains were further analyzed to 
investigate whether the levels of additional 
metabolites were significantly affected in 
response to YDR109C gene deletion. Principal 
Component Analysis (PCA) of the mTIC-
normalized negative and positive mode data 
produced clusters separating WT and ydr109cΔ 
samples in a PC1 vs. PC2 plot in which all the 
replicates were within the 95% CI of their group 
centroids (Figs. 3A and 3B). Since PCA is an 
unsupervised visualization method, which is not 
guaranteed to well preserve the distances 
between the original, untransformed data points, 
the Partial Least Squares Discriminant Analysis 
(PLS-DA) supervised method was additionally 
used to investigate the separability between the 
sample groups and to find features important in 
differentiating the WT from the ydr109cΔ strain. 
The data showed clear separation of the WT and 
ydr109cΔ replicate groups using PLS-DA as 
well, with again all the replicates lying within 
the 95% CI of their respective group (Figs. 3C 
and 3D). Tables S1, S2, S3 and S4 contain a 
column with VIP scores for all the listed m/z 
features, reflecting their importance for PLS-DA 
separation of the WT and ydr109cΔ samples.  
Fold changes between the prototrophic 
WT and ydr109cΔ strains for each metabolite 
feature detected by ZIC-HILIC-ddMS2 and 
associated p-values were calculated using 
Welch’s t-test for unequal variances. 
Unexpectedly, the levels of as many as 92 and 
213 non-redundant metabolite features having 
m/z matches in the KEGG database were found 
to be changed at least 2-fold and with a p-value 
lower than 0.05 between the two strains in the 
negative and positive ionization modes, 
respectively. These numbers dropped to 26 and 
69 non-redundant metabolite features, 
respectively, when only features with additional 
m/z matches in the YMDB (19) were retained 
(Tables S1 and S3). Interestingly, several 
intermediates of the arginine synthesis pathway 
(N-acetyl-glutamate, ornithine, N-
acetylornithine, and N-acetyl-glutamate-
semialdehyde; Table S3) as well as several 
intermediates or derivatives of the kynurenine 
pathway for tryptophan catabolism (tryptophan 
itself, formylkynurenine, kynurenine, 3-
hydroxykynurenine, 3-hydroxyanthranilate, 
kynurenic acid, xanthurenic acid) ranged among 
the most significantly changed metabolites and, 
accordingly, some of those metabolites also had 
the highest scores in the PLS-DA. Given that 
those two pathways do not share any obvious 
connection with ribulose metabolism, we wanted 
to test whether similar changes could also be 
found upon YDR109C deletion in a different 
genetic background. We therefore also analyzed 
the ZIC-HILIC-ddMS2 data obtained for the 
auxotrophic WT and ydr109cΔ strains using 
multivariate and univariate statistics. In strong 
contrast to the prototrophic strains, the 
auxotrophic WT and ydr109cΔ strains showed 
much more similar metabolite profiles and 
corresponding samples did not form two 
separate clusters after PCA of the non-targeted 
metabolomics data obtained in negative or 
positive ionization mode (data not shown). Data 
analysis using the Welch’s t-test yielded 
nevertheless 8 and 21 significantly changed 
metabolite features (2 and 11 metabolite features 
when retaining only features with matches in 
both the KEGG and YMDB databases; Tables 
S2 and S4) in the auxotrophic ydr109cΔ strain 
compared to the WT strain in the negative and 
positive ionization mode, respectively. 
Comparing those changes to the ones observed 
for the prototrophic strains, only two metabolites 
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differed significantly between WT and KO in 
both genetic backgrounds in the negative mode 
(ribulose and ribitol) and nine metabolites were 
changed significantly in the KO vs. the WT 
strain in both genetic backgrounds in the 
positive mode (all metabolites listed in Table S4, 
except for 4-aminobutanoate and methionine 
sulfoxide). This showed that, as already 
described above, the ribulose and ribitol 
accumulations observed upon YDR109C deletion 
are robust changes likely to be specifically 
linked to this gene, whereas the metabolite 
changes observed in the arginine synthesis and 
tryptophan degradation pathways upon 
YDR109C deletion in the prototrophic strain are 
background specific. 
To further test which of the KO vs. WT 
metabolite changes in the prototrophic 
background were specifically caused by 
YDR109C deficiency, we generated a rescue 
strain (KOres or ydr109cΔ rescue) expressing 
YDR109C under the control of the endogenous 
promoter from a low-copy number plasmid 
conferring resistance to hygromycin B (p41Hyg 
1-F) in the ydr109cΔ background. Using 
quantative RT-PCR, we measured two-times 
higher YDR109C transcript levels in the rescue 
strain than in the corresponding wild-type strain 
(Fig. 1), validating the rescue strategy at the 
gene expression level. The YDR109C transcript 
was not detectable in a ydr109cΔ strain 
transformed with an empty plasmid (KOcnt or 
ydr109cΔ empty plasmid; Fig. 1). Polar 
metabolites extracted from the KOcnt and KOres 
strains were analyzed using ZIC-HILIC-ddMS2 
in positive and negative ionization mode. 
Although ribulose levels were consistently lower 
in the rescue strain than in the empty vector 
control strain (KOcnt/KOres ratio of 1.7 with a 
p-value of 0.0000005 calculated using the 
unequal variances Welch’s t-test; n=6), the 
rescue efficiency was only very partial at the 
metabolite level given the more than 30-fold 
higher levels of ribulose measured in the non-
transformed ydr109cΔ strain compared to the 
prototrophic wild-type control strain (Table S1). 
Except for N-acetyl-glutamate, N-acetyl-
glutamate 5-semialdehyde, ribitol, and 
deoxyribose, other metabolite changes observed 
in the prototrophic ydr109cΔ strain compared to 
wild-type were either not found or were found to 
vary in opposite direction in the KOcnt vs. 
KOres strain comparison (data not shown). Such 
results typically would suggest that those 
supplementary changes in the metabolite profiles 
of the original strains were due to the presence 
of secondary mutations present in the ydr109cΔ 
mutant, but not in the wild-type control strain. 
However, given the incomplete rescue of the 
ribulose metabolic phenotype, it seems that the 
rescue plasmid used led, for reasons that remain 
unclear, to the formation of a transcript that does 
not allow reconstitution of wild-type protein 
and/or wild-type enzyme activity levels, 
potentially explaining why other metabolic 
changes were not rescued.  
We next adapted a recently published 
SIL workflow (20) for improved untargeted 
metabolomics data analysis to our experimental 
model. Our prototrophic wild-type and ydr109cΔ 
strains were cultivated in parallel in minimal 
controlled medium supplemented either with 
non-labeled D-glucose or with U-13C-D-glucose 
as the sole carbon source (both the non-labeled 
and the fully labeled glucose were added at a 
final concentration of 2% (w/v)). Polar 
metabolites were extracted from the four 
cultivations and the 13C-labeled extracts derived 
from both the wild-type and the ydr109cΔ cells 
were pooled. This labeled pooled sample was 
spiked as an internal standard into the individual 
non-labeled metabolite extracts of the wild-type 
and ydr109cΔ strains and the spiked samples 
were analyzed by ZIC-HILIC-ddMS2 in positive 
or negative ionization mode. Data analysis was 
performed using an extended version of the 
MetExtract software (20,21). The data filtering 
based on SIL specific isotopic patterns and 
subsequent grouping of 12C and 13C feature pairs 
greatly enriches the processed mass 
spectrometry dataset in small molecules that are 
produced intracellularly and assists with 
metabolite identification by the number of 
carbon atoms that can be deduced for each 
metabolite from the difference in mass between 
the 13C and 12C ions. Using this strategy we 
again confirmed that ribulose (as well as ribitol) 
is produced endogenously by S. cerevisiae cells 
from D-glucose, but we also could extend this 
conclusion to all the other detected metabolite 
features that had a matching U-13C counterpart 
and could use this information to improve 
metabolite identification in our untargeted 
metabolomics dataset, with a focus on the 
metabolites that were found up- or 
downregulated in the ydr109cΔ strain (Tables S1 
and S3). This added an additional level of 
confidence to identifications for metabolites that 
were not represented in our in-house metabolite 
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library (and conversely also allowed to question 
metabolite identifications based on accurate 
mass matches in the KEGG and YMDB 
databases; see for example the most significantly 
changed metabolite, detected in the positive 
mode, identified as N-acetyl-L-glutamate-5-
semialdehyde by KEGG and YMDB accurate 
mass match, but for which the co-cultivation 
method revealed a carbon number that does not 
concur with this identification). Notably, the 
identity of some of the arginine synthesis 
pathway intermediates (N-acetylglutamate and 
ornithine) as well as of the kynurenine pathway 
intermediates or derivatives (tryptophan, 
formylkynurenine, kynurenine, 3-
hydroxykynurenine, 3-hydroxyanthranilate, 
kynurenic acid, xanthurenic acid) that were 
found to significantly change between the 
prototrophic WT and ydr109cΔ strains was in 
this way further consolidated (Tables S1 and 
S3). 
Deficiency of another FGGY protein 
family member encoded by the S. cerevisiae 
genome, Mpa43, does not lead to pentose 
accumulation–BLAST searches revealed that the 
S. cerevisiae genome encodes a protein (Mpa43) 
that is highly similar to the Ydr109c protein. 
Mpa43 is a smaller protein (542 aa) than 
Ydr109c (715 aa) and the N-terminal and C-
terminal sequences of the two proteins do not 
share sequence similarity. However, about 70% 
of the Ydr109c protein sequence (from amino 
acids 41-552) aligns well with Mpa43, showing 
28% sequence identity. Mpa43 also contains the 
conserved FGGY_N and FGGY_C domains. 
While nothing is known on the subcellular 
localization of Ydr109c, the Mpa43 protein was 
detected in highly purified mitochondria in high-
throughput studies (22,23). This is in 
disagreement with scores obtained with the 
TargetP program (24), which predicted Mpa43 
to be neither mitochondrial nor targeted to the 
secretory pathway, while for Ydr109c it 
computed the highest score for a mitochondrial 
localization (with, however, a low reliability). 
Given the protein sequence similarities between 
Ydr109c and Mpa43, we also analyzed 
metabolite extracts derived from a prototrophic 
strain knocked out for the MPA43 gene. In 
strong contrast to the findings described for the 
ydr109cΔ strain, the metabolite profile of the 
mpa43Δ strain showed only few significant 
metabolite level changes compared to the wild-
type strain and the mpa43Δ and wild-type 
metabolite profiles were not clearly separable 
using PCA (data not shown). Importantly, we 
could not detect an increase in free ribulose (or 
any other pentose) or ribitol levels in the 
mpa43Δ strain, suggesting that Ydr109c and 
Mpa43 are not isozymes. 
FGGY silencing in Human Embryonic 
Kidney cells leads to increased ribulose levels 
under certain conditions–The human genome 
contains a homolog of the yeast YDR109C gene, 
designated FGGY (40 % identity at the amino 
acid sequence level). As for the yeast protein, 
the molecular and biological roles of the human 
FGGY protein remain largely unknown. Based 
on our results in the yeast model, we searched 
for ribulose or other pentoses in metabolite 
extracts derived from HEK293 cells and from 
the hepatocyte cell line PH5CH8 using a 
targeted ZIC-HILIC-MS method. Extracted ion 
chromatograms (m/z = 149.0445) did not reveal 
the presence of ribulose in either the HEK293 or 
PH5CH8 cells when cultivated in DMEM 
medium supplemented with 5 mM D-glucose (in 
addition to the 25 mM glucose already contained 
in the DMEM formulation). The analyses were 
repeated in a HEK293 cell line stably expressing 
an FGGY-specific small hairpin RNA (shRNA) 
and in PH5CH8 cells transfected with FGGY-
specific small interfering RNAs (siRNAs). 
Despite a knockdown efficiency of about 60% in 
both cell types at the mRNA level (Fig. 4A and 
data not shown), ribulose could not be detected 
in any of the conditions tested. 
Given that ribulose was shown not to be 
taken up by human fibroblasts (25), we 
supplemented the basal cell culture medium with 
the potential ribulose precursors ribitol, both at a 
concentration of 5 or 10 mM, for the PH5CH8 
and HEK293 cells. In addition, we tested 
supplementation with 5 mM D-arabinose for the 
HEK293 cells. D-arabinose and ribitol can be 
metabolized in bacteria via pathways that 
comprise D-ribulose as an intermediate (26,27). 
Although we detected intracellular D-arabinose 
in the HEK293 cells cultivated in the presence of 
this pentose, we did not detect any intracellular 
ribulose 48 hours after the addition of D-
arabinose, without or with FGGY silencing. In 
contrast, in HEK293 cells cultivated in the 
presence of ribitol, we detected ribulose and the 
latter accumulated to higher levels in cells 
knocked down for FGGY (Fig. 4B). When non-
labeled ribitol was replaced by U-13C-ribitol in 
these experiments, a + 5 m/z shift was observed 
for the peak co-eluting with a ribulose standard 
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(not shown), confirming the identity of the peak 
as ribulose and showing that the ribulose 
measured derived from the supplemented ribitol 
under the cultivation conditions used. PH5CH8 
cells cultivated in the presence of ribitol did not 
produce measurable amounts of ribulose, even 
when FGGY was knocked down (data not 
shown). Taken together these results indicate 
that free ribulose is not produced in detectable 
amounts by the cell lines tested here under 
standard cultivation conditions, but that in 
certain cell types ribitol can be oxidized to 
ribulose. The increased ribulose levels measured 
in HEK293 FGGY knockdown cells cultivated in 
the presence of ribitol also confirm that FGGY 
can use ribulose as a substrate in a living cell.  
Recombinant yeast Ydr109c and human 
FGGY specifically convert D-ribulose to D-
ribulose-5-phosphate in the presence of ATP–
Our findings in yeast and mammalian cells 
suggested that ribulose is an endogenous 
substrate of the yeast Ydr109c and human 
FGGY proteins. Being in addition members of 
the FGGY family of sugar kinases, this strongly 
indicated that Ydr109c and FGGY are 
ribulokinases. To confirm this hypothesis and 
find out whether the enzymes act on D-ribulose 
or L-ribulose (not separated by our liquid 
chromatography method preceding the MS 
analysis), we expressed recombinant N-
terminally His-tagged Ydr109c and FGGY in a 
bacterial system and purified the proteins by 
Ni2+ affinity chromatography for subsequent 
enzyme activity assays.  
The purified His-Ydr109c protein 
generated a band at the expected size (83kDa) as 
shown by SDS-PAGE analysis and Western 
blotting using an anti-His antibody (Figs. 5A and 
5B). Using the PK/LDH coupled 
spectrophotometric assay, we tested the putative 
kinase activity of recombinant Ydr109c on 19 
different sugars or sugar derivatives (9 pentoses, 
4 sugar alcohols, D-glucose, D-gluconate, D-
glycerol, D-ribulose-5-P, D-ribose-1-P, and D-
ribose-5-P) at a concentration of 1 mM (Table 
1). Enzymatic activity was only detected in the 
presence of D-ribulose. With this substrate, the 
enzyme showed Michaelis-Menten kinetics and 
we determined a Km of 217 ± 15 µM and a Vmax 
of 22 ± 2 µmol.min-1.mg protein-1 (means ± SDs, 
n = 3). The recombinant His-Ydr109c protein 
was very unstable and lost activity upon freezing 
and thawing or during prolonged purification 
procedures. Therefore, enzyme activity assays 
with recombinant His-Ydr109c were carried out 
within 24 hours after affinity purification, 
without prior desalting, keeping the protein at 4 
°C throughout the purification procedure and 
until the measurements.  
The human recombinant His-FGGY 
protein was, unlike its yeast homolog, very 
stable. SDS-PAGE and Western blot analyses of 
the fractions collected after Ni2+ affinity 
purification and desalting showed a major band 
at about 50 kDa, i.e. below the expected mass of 
64 kDa for the His-FGGY protein (Fig. 5C and 
5D). LC-MS/MS analysis after trypsin digestion 
of the purified protein preparation confirmed, 
however, the sequence identity of the protein, 
the detected peptides showing the best match to 
the Q96C11-1 (Uniprot) sequence, with 76% 
sequence coverage (data not shown). The reason 
for protein migration at a lower apparent 
molecular weight during SDS-PAGE remains 
unknown. To determine the substrate specificity 
of the enzyme, we screened the same 19 
compounds that we used for Ydr109c substrate 
specificity testing, at two different 
concentrations (100 µM and 1 mM). The 
recombinant human FGGY protein showed 
clearly the highest activity with D-ribulose, but 
also phosphorylated ribitol and L-ribulose at 
lower rates (Table 1). We determined a Km of 97 
± 25 µM and a Vmax of 5.6 ± 0.4 µmol.min-1.mg 
protein-1 (means ± SDs, n = 3) for the D-
ribulokinase activity and a Km of 1468 ± 541 µM 
and a Vmax of 2.4 ± 0.3 µmol.min-1.mg protein-1 
(means ± SDs, n = 4) for the ribitol kinase 
activity. Human FGGY is thus 35-fold more 
efficient as a D-ribulokinase than as a ribitol 
kinase. Purified human His-FGGY protein was 
found to be enzymatically active even after one 
year of storage at -80 °C.  
The identity of the pentose phosphate 
product formed by human recombinant FGGY 
when incubated with its preferred substrate D-
ribulose was confirmed by analyzing the 
enzymatic reaction mixture by LC-MS/MS. A 
major compound contained in this mixture 
displayed a detected mass corresponding to the 
theoretical mass of ribulose-5-P, co-eluted with 
a D-ribulose-5-phosphate analytical standard, 
and showed the same MS2 fragmentation pattern 
as this analytical standard (Figs. 6A and 6B). 
After incubation of recombinant FGGY with 
ribitol or L-ribulose (both at a concentration of 1 
mM), we also detected the masses of the 
expected ribitol-5-phosphate (theoretical m/z 
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231.0264; detected m/z 231.0273) or L-ribulose-
5-phosphate (theoretical m/z 229.0108; detected 
m/z 229.0116) products in the reaction mixtures 
(data not shown); further support (co-elution and 
MS2 spectrum match with standards) for these 
compound identities could, however, not be 
gathered as appropriate analytical standards were 
not commercially available. 
Yeast Ydr109c and human FGGY are 
homologs of a proteobacterial D-ribulokinase 
involved in ribitol metabolism–A specific D-
ribulokinase was first reported in Klebsiella 
aerogenes by Neuberger et al. in 1981 (28) and 
the gene encoding this enzyme (rbtK) was 
cloned in 1998 from Klebsiella pneumoniae 
(27). Certain enteric bacteria, including many 
Klebsiella strains, but only a few Escherichia 
coli strains (e.g. E. coli C, but not E. coli K12 
and B), can use the pentitols D-arabitol and 
ribitol as sole carbon sources. Although both 
pentitols are catabolized via oxidation followed 
by phosphorylation, specific transporters, 
repressors and enzymes encoded by two 
different operons govern the metabolism of each 
of these pentitols. The K. pneumoniae ribitol 
operon comprises a ribitol transporter, a ribitol 
dehydrogenase, the D-ribulokinase, and a 
repressor that is induced by D-ribulose (27). The 
existence of this ribitol operon greatly helped us 
to identify ‘true’ D-ribulokinases in other 
bacterial species and we found D-ribulokinase 
genes clustering with ribitol dehydrogenase 
genes in other gamma-proteobacteria, alpha-
proteobacteria and the beta-proteobacterium 
Burkholderia sp. Ch1-1 using the SEED viewer 
browser (29). The K. pneumoniae D-
ribulokinase sequence (UniProt A6TBJ4) was 
also used to identify D-ribulokinase ortholog 
candidates in eukaryotic species using blastp 
searches. This analysis showed that D-
ribulokinase is conserved in many animal 
species, fungi, and plants with close to 40% 
amino acid sequence identity or more to the 
bacterial sequence. Among those ortholog 
candidates, S. cerevisiae Ydr109c shared 39% 
amino acid sequence identity (E-value of 6e-
114) and human FGGY (RefSeq isoform b or 
UniProt Q96C11-1) shared 42% amino acid 
sequence identity (E-value of 7e-143) with the 
bacterial D-ribulokinase protein. The S. 
cerevisiae protein Mpa43 also aligned with the 
latter, but showed lower amino acid sequence 
conservation (25% identity; E-value of 2e-31). 
Figure 7 shows a multiple sequence 
alignment (MSA) of D-ribulokinase candidate 
sequences selected across different kingdoms of 
life (gamma-, alpha-, and beta-proteobacteria, 
yeast, drosophila, zebrafish, Arabidopsis, mouse, 
and human). It also includes the yeast Mpa43 
protein sequence. Despite the considerable 
evolutionary distance between most of the 
chosen species, highly conserved sequence 
motifs can be found over the entire length of the 
D-ribulokinase sequence. Strikingly, the yeast 
Ydr109c protein shows, however, an about 20 
amino acid N-terminal sequence extension and 
an about 100 amino acid sequence insertion 
towards the C-terminal extremity that are found 
in none of the other D-ribulokinase protein 
sequences analyzed. While the N-terminal 
sequence may be involved in targeting the 
protein to a specific subcellular compartment, 
we can currently not speculate on the role of the 
C-terminal insertion. Using the strain sequence 
alignment function in SGD, we found that the 20 
amino acid N-terminal extension and the 100 
amino acid C-terminal insertion are highly 
conserved within the S. cerevisiae species. Using 
the fungal sequence alignment function in SGD, 
it appears that Ydr109c homologs in other 
budding yeasts such as Saccharomyces 
paradoxus, Saccharomyces bayanus, 
Saccharomyces uvarum, and Saccharomyces 
mikatae also comprise an N-terminal extension 
and C-terminal insertion that is absent from 
bacterial, animal and plant D-ribulokinase 
proteins (in many of the budding yeast species 
analyzed, the Ydr109c homologous proteins 
have a size of more than 700 amino acids as 
opposed to the smaller protein size of around 
550 amino acids displayed by bacterial, animal 
and plant D-ribulokinase proteins); these 
additional sequences show, however, as opposed 
to the rest of the Ydr109c protein sequence, no 
significant sequence similarity between the 
different yeast species analysed. These 
observations suggest that the additional 
sequences found in the S. cerevisiae Ydr109c 
protein are ‘real’ and do not result from 
erroneous gene structure annotation or genome 
sequencing errors. This was further consolidated 
by the fact that our own sequencing of the 
Ydr109c ORF that we PCR-amplified from S. 
cerevisiae genomic DNA yielded a result that 
was in perfect agreement with the sequence 
contained in the SGD database. 
Zhang et al. performed a detailed 
bioinformatics analysis of proteins belonging to 
the FGGY carbohydrate kinase family to better 
understand the evolutionary mechanisms 
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underlying functional diversification in this 
family (3). They assembled a Confidently 
Annotated Reference Set (CARS) of 446 FGGY 
proteins with high-quality functional annotations 
based not only on sequence homology, but also 
on experimental evidence (if available) and on 
genomic as well as pathway context. The CARS 
protein set comprised only 3 eukaryotic FGGY 
family members (1 glycerol kinase and 2 
xylulose kinases), all the other proteins being of 
bacterial origin. The CARS proteins were used 
for phylogenetic analyses and to predict amino 
acid residue positions that are important for the 
recognition of a specific substrate within 
isofunctional groups of proteins (also referred to 
as specificity-determining positions or SDPs). 
Here, we extended the phylogenetic analysis of 
this CARS protein set by adding the protein 
sequences that we confidently identified as D-
ribulokinases and used for the MSA shown in 
Fig. 7, including the S. cerevisiae Ydr109c and 
human FGGY proteins. As expected, the 
resulting phylogenetic tree displayed a very 
similar topology to the one constructed by 
Zhang et al. (3), with most of the proteins 
forming tight clusters according to their 
enzymatic function (e.g. glycerol kinase cluster, 
xylulokinase cluster) and suggesting a divergent 
evolution model (Fig. S1). We also found a more 
complex branching for the L-ribulokinase 
(AraB) group whose members split into several 
subgroups interspersed with the gluconokinase 
and D-ribulokinase groups. All the D-
ribulokinase sequences that we included 
additionally in the phylogenetic analysis cluster 
with the D-ribulokinase group that evolved from 
one of the L-ribulokinase subgroups (Fig. S1). 
This suggests that the prokaryotic and eukaryotic 
D-ribulokinases evolved from the same common 
ancestor by divergent evolution. 
We further extended our D-ribulokinase 
sequence analyses by applying the 
GroupSim+Conswin method (30) for the 
identification of sequence positions determining 
the sugar substrate specificity (SDPs) of D-
ribulokinase proteins. The GroupSim method 
predicts SDPs based on sequence information 
only. ConsWin is a heuristic that can be 
combined with the GroupSim method to improve 
SDP predictions by taking into account sequence 
conservation of neighboring amino acids. SDP 
predictions were made by applying 
GroupSim+Conswin to the MSA built from our 
extended CARS dataset (enriched in D-
ribulokinase sequences), where sequences were 
grouped according to the high-quality functional 
annotations (for isofunctional groups spanning 
multiple subgroups only the subgroup with the 
highest number of protein sequences was kept; 
see Experimental Procedures for more details). 
The top 20 SDPs identified for the yeast and 
human D-ribulokinases (Ydr109c and FGGY, 
respectively) are highlighted in red in Figure 7. 
The majority of these SDPs correspond to 
residues that are highly conserved between 
prokaryotic and eukaryotic D-ribulokinases (Fig. 
7). It should be noted that among the 12 SDPs 
with strictly conserved residues in all of the D-
ribulokinase sequences shown in Figure 7, three 
positions contain different residues in the yeast 
Mpa43 protein (Ser to Val, Cys to Gly, and Ala 
to Ser substitutions), which, together with the 
absence of ribulose accumulation in the yeast 
mpa43Δ deletion strain, further supports that this 
protein most likely does not function as a D-
ribulokinase. As described below, these 
predictions, as well as structural predictions 
provided the basis for the identification of a 
sequence motif that appears to be specific for D-
ribulokinases. 
Structural homology modeling of yeast 
and human D-ribulokinases and definition of a 
D-ribulokinase signature motif–Three-
dimensional structural homology models of the 
yeast Ydr109c and human FGGY proteins were 
generated using the crystal structure of a 
Yersinia pseudotuberculosis FGGY 
carbohydrate kinase (PDB ID 3L0Q chain A and 
3GGA chain A, for FGGY and Ydr109c, 
respectively) as a template (Fig. 8). Of the 20 
proteins with an FGGY_N domain for which 
three-dimensional structures have been 
deposited in PDB, this Y. pseudotuberculosis 
protein Q665C6 has the highest sequence 
similarity to the yeast Ydr109c and human 
FGGY proteins (39 % and 51% amino acid 
sequence identity, respectively). A D-xylulose 
molecule is contained in the putative active site 
of the PDB 3L0Q crystal structure and the 
protein is annotated as a xylulose kinase in PDB. 
Sequence analysis clearly suggests, however, 
that this protein is in fact a D-ribulokinase, given 
the high sequence similarity with the yeast 
Ydr109c and human FGGY proteins and the 
presence of the TCSLV motif, identified here as 
a D-ribulokinase signature motif as described 
below. 
We used the available ligand 
information from the 3L0Q structure to position 
D-xylulose within our human FGGY structural 
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models (Fig. 8C) and identify the localization of 
the active site as well as amino acid residues 
important for substrate binding and/or catalysis. 
For yeast Ydr109c, a molecular docking 
approach was used to determine both ligand 
position and orientation, as the original structure 
of 3GGA chain A was not bound to any ligand 
molecule. As for other FGGY carbohydrate 
kinases, a catalytic cleft is formed at the 
interface between the two conserved actin-like 
ATPase domains (Pfam domains FGGY_N and 
FGGY_C). It has been shown for other members 
of the family that the sugar substrate binds 
deeply within the catalytic pocket and interacts 
mainly with residues of the FGGY_N domain 
whereas the ATP co-substrate binds more 
towards the opening of the cleft interacting with 
both the FGGY_N and FGGY_C domains (31). 
Accordingly, the xylulose ligand in our D-
ribulokinase structural models contacts only 
residues of the FGGY_N domain (Fig. 8C for 
the human protein; not shown for the yeast 
protein). Using the human FGGY homology 
model, we found that the residues Thr86, Ile259, 
Asp260, Ala261, and His262 can take part in 
Van-der-Waals interactions and that Cys87, 
Asp260, and Glu328 have the potential to form 
hydrogen bonds with the substrate (residues 
highlighted in yellow in Fig. 7). Based on the 
Ydr109c homology model, the residues Cys117, 
Ile301, and Asp302 are potentially involved in 
Van-der-Waals interactions and Thr116, 
Cys117, Lys224, Asp302, Tyr304, Glu378, and 
Arg449 potentially form hydrogen bonds with 
the substrate (also highlighted in yellow in Fig. 
7). It can be seen in Fig. 7, that all the residues 
predicted to be important for sugar substrate 
binding using the structural models, coincide or 
are found in close proximity to identified SDPs. 
Mapping the top 20 SDPs onto the human and 
yeast homology models, it can also be seen in 
Figs. 8A and 8B that most of them, although 
sometimes distant from each other in sequence, 
are located in or near the catalytic cleft in the 
structural models. 
Two highly conserved motifs in the 
MSA shown in Fig. 7 stand out by featuring 
residues important for substrate specificity or 
binding as predicted by both the SDP or 
structural modelling approaches: the TCSLV 
motif (starting with Thr86 in FGGY and Thr116 
in Ydr109c) and the IDAH/Y motif (starting 
with Ile259 in FGGY and Ile301 in Ydr109c). 
Using the master MSA used for construction of 
the phylogenetic tree, we found that the TCSLV 
motif is strictly conserved in the entire D-
ribulokinase cluster of sequences, but not found 
in other isofunctional groups of the FGGY 
protein family, whereas the IDAH/Y motif was 
also retrieved in a few L-Ribulokinase 
sequences. The TCSLV motif was further 
validated as a D-ribulokinase signature motif 
using a second master MSA based on more than 
600 reviewed FGGY family members retrieved 
from UniProt (see Experimental Procedures). 
Interestingly, the Val residue of this signature 
motif is replaced by an Ala residue in the Mpa43 
protein. This second master MSA also allowed 
us to confirm the existence of multiple 
distinctive subgroups within the L-ribulokinase 
functional group and to identify additional 
conserved sequence motifs distinguishing the L-
ribulokinase subgroups in a homologous 
position to the TCSLV motif in the D-
ribulokinase group (namely TGTST, TSST, 
TGSSP, TGSTP, MMHGY and TACTM). 
Zhang et al (3) also made SDP predictions and, 
based on structural information available in 
PDB, selected five (generally non-consecutive) 
SDPs as ‘signature residues’ for all the 
subgroups in their FGGY CARS dataset. Of the 
five SDPs selected for the D-ribulokinase 
subgroup (T, C, E, A, Y), three (T, E, A) 
coincide with SDPs predicted using a different 
method in this study (see Experimental 
Procedures section) and two (T, C) are 
comprised in the D-ribulokinase signature motif 
defined and validated here using protein datasets 
containing a higher number of evolutionary 
more distant D-ribulokinase sequences than in 
the study by Zhang et al. (3). 
Finally, using the described D-
ribulokinase and L-ribulokinase sequence 
motifs, we analysed the phylogenetic spread of 
these kinases based on FGGY_N domain 
sequences retrieved for 34 different phyla from 
the Pfam database, as described in the 
Experimental Procedures section. Strikingly, as 
can be seen in Fig. 9, D-ribulokinase is much 
more widely conserved in eukaryotes (including 
animals, plants and fungi), whereas L-
ribulokinases are more broadly distributed in 
prokaryotes. In prokaryotes, D-ribulokinase is 
found only in proteobacterial lineages as well as 
in Verrucomicrobia and Armatimonadetes. No 
ribulokinase homologs (neither D- nor L-) were 
found in Archaea. 
 
DISCUSSION  
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Identification of YDR109C and FGGY 
as genes encoding a specific eukaryotic D-
ribulokinase–In this study, we aimed at 
identifying the molecular and biological roles of 
a conserved protein of unknown function 
(Ydr109c in yeast and FGGY in humans), 
member of the FGGY protein family of 
carbohydrate kinases. To reach this objective, 
we started by comparing the polar metabolite 
profiles of yeast cells deleted in the YDR109C 
gene and of wild-type control cells using non-
targeted LC-HRMS or LC-MS/MS. One of the 
most prominent and robust changes, observed in 
both a prototrophic and an auxotrophic genetic 
background and partially rescued when restoring 
YDR109C expression in the deletion strain, was 
the accumulation, in the ydr109cΔ strain, of a 
pentose identified as ribulose by comparing 
elution time, accurate mass and MS2 
fragmentation pattern with those of a ribulose 
standard. Ribulose did not accumulate in a yeast 
strain deleted for a closely related protein 
encoded by the S. cerevisiae genome (Mpa43), 
suggesting that Ydr109c is the only kinase 
responsible for free ribulose conversion in this 
organism. Labeling experiments in which U-13C-
D-glucose was used as the sole carbon source 
confirmed that yeast cells can produce free 
ribulose from D-glucose and that this pentose 
accumulates upon YDR109C deletion. In 
contrast, we could not detect free ribulose in the 
two human cell lines tested in this study 
(HEK293 and PH5CH8), even after silencing of 
the YDR109C homologous gene FGGY. In the 
HEK293 cells, but not in the PH5CH8 cells, 
ribulose became detectable upon 
supplementation of the cultivation medium with 
ribitol. Under those conditions, FGGY 
knockdown led to increased ribulose levels in 
the HEK293 cells. Finally, in vitro enzymatic 
assays with recombinant purified Ydr109c and 
FGGY proteins confirmed that both act as ATP-
dependent sugar kinases and showed that D-
ribulose is by far the best substrate for those 
enzymes. Taken together, these findings 
demonstrate that Ydr109c and FGGY 
phosphorylate D-ribulose in budding yeast and 
human cells, respectively, and associate the 
eukaryotic D-ribulokinase activity, which had 
been reported to exist in guinea pig liver before 
(32,33), with a protein sequence. Although 
numerous other metabolites were significantly 
changed in the ydr109cΔ prototrophic strain 
compared to the corresponding wild-type strain 
in addition to ribulose, the facts that we didn’t 
observe a majority of those other changes in a 
different genetic background and that they were 
not restored in a prototrophic rescue strain, do 
not allow to firmly associate those changes with 
the YDR109C gene based on our current results. 
D-Ribulokinase is the major 
ribulokinase in eukaryotes, while L-ribulokinase 
is more widely distributed in prokaryotes–Prior 
to this study, a specific D-ribulokinase involved 
in ribitol metabolism had been cloned from K. 
pneumoniae (27). The D-ribulokinases from 
Aerobacter aerogenes (34) and K. aerogenes 
(28) have been extensively purified and 
characterized. The enzyme was shown to be 
active as a homodimer and Km values for D-
ribulose of 85 µM and 400 µM were reported for 
the Aerobacter and Klebsiella enzymes, 
respectively. A Vmax of 71 µmol.min-1.mg 
protein-1 was found for the Klebsiella D-
ribulokinase and this enzyme showed low side 
activities with ribitol (Km of 220 mM, Vmax of 12 
µmol.min-1.mg protein-1) and D-arabitol (Km of 
140 mM, Vmax of 6.6 µmol.min-1.mg protein-1) 
(28). The kinetic properties for D-ribulose are 
similar to the ones determined in this study for 
the S. cerevisiae and human D-ribulokinases (Km 
of 217 µM and Vmax of 22 µmol.min-1.mg 
protein-1 for Ydr109c; Km of 97 µM and Vmax of 
5.6 µmol.min-1.mg protein-1 for FGGY). For the 
human enzyme, we also found lower, but 
detectable activitities with ribitol and L-ribulose; 
D-arabitol was not tested as it could not be 
obtained commercially at the time of this study. 
The highly similar enzymatic properties shared 
by those enzymes from evolutionary divergent 
organisms, in addition to the high sequence 
identity, support that they are othologous 
proteins. 
The molecular identification of the 
eukaryotic D-ribulokinase allowed us to 
incorporate eukaryotic D-ribulokinase sequences 
into phylogenetic analyses. In agreement with an 
extensive previous study on the evolution of 
functional specificities of prokaryotic members 
of the FGGY carbohydrate kinase family (3), we 
found that eukaryotic D-ribulokinases, just as 
the bacterial D-ribulokinases, have evolved from 
an L-ribulokinase (AraB) FGGY subgroup. 
Based on our sequence and structural analyses, 
we also defined and validated a D-ribulokinase 
signature motif (TCSLV), which can now be 
used to functionally identify FGGY protein 
sequences as D-ribulokinase with high 
confidence. Using this motif, we found that D-
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ribulokinase is conserved in only a few bacterial 
lineages, while it is widespread in eukaryotes 
(see Fig. 9). Notable exceptions of eukaryotic 
species that do not encode a D-ribulokinase are 
Schizosaccharomyces pombe, Caenorhabditis 
elegans, and trypanosomatid species. By 
contrast, L-ribulokinase, which is required for L-
arabinose metabolism in bacteria, is much more 
broadly conserved in prokaryotes than D-
ribulokinase, but is not found in eukaryotic 
species, except for trypanosomatid species such 
as Leptomonas, Trypanosoma, and Leishmania 
(Fig. 9); the genomes of Schizosaccharomyces 
pombe and Caenorhabditis elegans do not 
encode either L- or D-ribulokinase. In summary, 
while L-ribulokinase is more broadly distributed 
in prokaryotes, D-ribulokinase is more broadly 
conserved in eukaryotes. Bacterial species that 
encode D-ribulokinase, can also encode L-
ribulokinase (e.g. K. pneumoniae), but many 
bacterial species encode only L-ribulokinase. 
Similarly, the trypanosomatid species that 
encode L-ribulokinase, do not encode D-
ribulokinase; unlike for many bacteria, however, 
the eukaryotic genomes that contain a D-
ribulokinase gene, do not contain an L-
ribulokinase gene. So, whereas bacterial 
genomes can contain two types of ribulokinases, 
eukaryotic genomes generally encode either the 
D- or the L-ribulokinase form (Fig. 9). 
While this study on eukaryotic proteins 
and previous studies on bacterial proteins 
(28,34) have shown that D-ribulokinase is highly 
specific for D-ribulose, L-ribulokinase is much 
more promiscuous in terms of sugar substrate 
specificity. E. coli L-ribulokinase (AraB) for 
example has been reported to use D-ribulose 
with a catalytic efficiency that is only 2-3-fold 
lower than its best substrate L-ribulose (35). In 
addition, AraB showed significant activity with 
L-xylulose, L-arabitol and ribitol and also acted 
on D-xylulose (35). This enzyme could therefore 
also be designated 2-ketopentokinase. The 
substrate promiscuity of L-ribulokinase as well 
as the significant sequence similarity between L-
ribulokinase and D-ribulokinase are certainly the 
reasons for many misannotations of D-
ribulokinases as L-ribulokinases and vice versa 
in gene and protein databases. Human FGGY for 
example displays more than 40% sequence 
identity with the K. pneumoniae D-ribulokinase, 
but also shares 25% sequence identity with the 
E. coli L-ribulokinase. Our enzymatic 
characterizations have clearly established the 
yeast and human ribulokinases as D-
ribulokinases. This study, and more particularly 
the D-ribulokinase sequence signature that we 
defined, should therefore help to correct the 
numerous database misannotations of FGGY 
protein family members, and more specifically 
of the ribulokinases. While the numerous 
bacterial species that only encode an L-
ribulokinase may not be able to grow on ribitol 
due to the lack of an inducible ribitol utilization 
pathway including the specific D-ribulokinase 
(see below), the substrate promiscuity of their L-
ribulokinase may ensure that free D-ribulose can 
be metabolized to a certain degree. Conversely, 
eukaryotic species, which for the most part only 
encode the more specific D-ribulokinase, should 
have a good metabolic capacity for D-ribulose, 
but more poorly, if at all, metabolize ribitol or L-
ribulose. 
Known and putative physiological roles 
of D-ribulokinase in bacteria and eukaryotes–
Figure 10 shows an overview of known and 
hypothetical reactions and pathways leading to 
the formation and metabolization of D-ribulose 
in various organisms. In K. pneumoniae and 
other enterobacteria that can use ribitol as sole 
carbon source (36), the D-ribulokinase gene is 
located in a ribitol utilization operon that 
contains in addition a ribitol transporter, a ribitol 
dehydrogenase, and a repressor; D-ribulose is an 
inducer of this operon (27). In addition, 
Elsinghorst and Mortlock reported in 1988 that 
in E. coli B, a D-ribulokinase gene is contained 
in the L-fucose regulon. The latter encodes the 
enzymes required for L-fucose utilization, but 
can also be induced by D-arabinose which can 
then be metabolized to D-ribulose and D-
ribulose-5-P via L-fucose isomerase and D-
ribulokinase, respectively (26). In the bacterial 
species that encode D-ribulokinase, this enzyme 
thus allows to direct carbon from ribitol or D-
arabinose to the pentose phosphate pathway via 
phosphorylation of the D-ribulose intermediate 
that is formed in the respective sugar utilization 
pathways. We found that D-ribulokinase 
sequences contained in either the ribitol or some 
enterobacterial L-fucose operons share high 
sequence similarity with yeast Ydr109c and 
human FGGY and contain the D-ribulokinase 
signature motif defined in this study. 
The only previous reports on a 
eukaryotic D-ribulokinase activity, in our 
knowledge, go back to the early 1960s, when 
Kameyama and Shimazono detected such an 
activity in guinea pig liver (32,33). A 
corresponding gene has not been cloned since. In 
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these early studies, the authors had become 
interested in the metabolism of D-ribulose in 
mammals after having found that D-ribulose can 
be formed from D-gluconate in guinea pig liver 
extracts (37). We did not find subsequent studies 
on this putative pathway, but D-gluconate to D-
ribulose conversion may be initiated by a side 
activity of L-gulonate 3-dehydrogenase 
(encoded by the CRYL1 gene), an enzyme 
involved in the pentose pathway for D-
glucuronate catabolism in mammals (38,39). 
The subsequent step in the pentose pathway is 
the decarboxylation of 3-dehydro-L-gulonate to 
L-xylulose (40); a similar reaction could convert 
3-dehydro-D-gluconate to D-ribulose. The gene 
encoding 3-dehydro-L-gulonate decarboxylase 
has not been identified yet. The mechanism of 
formation of D-gluconate in mammalian cells, if 
it occurs at all, also remains unclear. The 
existence of a mammalian pathway for D-
ribulose formation from D-gluconate remains 
therefore highly speculative. 
Using LC-MS-based metabolite 
profiling and isotopic labeling, we could 
measure D-ribulose formation from externally 
supplemented ribitol in human HEK293 cells, 
but not from glucose. By contrast, in S. 
cerevisiae, we were able to detect formation of 
D-ribulose from glucose, while the conversion 
of ribitol to D-ribulose was not observed in this 
organism. Our results suggest that, while yeast 
cells constantly produce detectable amounts of 
free D-ribulose under standard cultivation 
conditions from glucose, this may not be the 
case for mammalian cells. However, our 
observations in the HEK293 cells suggest that 
ribitol can serve as a precursor for D-ribulose at 
least in certain mammalian cell types; D-ribulose 
was not detected in PH5CH8 cells (this study) or 
human fibroblasts (25) cultivated in the presence 
of ribitol and no ribitol dehydrogenase activity 
could be detected in human erythrocyte lysates 
(25). Ribitol dehydrogenase activity has, 
however, been measured during early studies 
with partially purified enzyme preparations from 
rat liver (41) and from guinea pig liver 
mitochondria (42). Comparing gene expression 
profiles of HEK293 cells and PH5CH8 cells 
could be a promising strategy to identify the 
putative dehydrogenase responsible for the 
oxidation of ribitol to D-ribulose in certain 
mammalian cell types. The prototrophic yeast 
strain used in this study did not grow in rich 
medium (yeast extract and peptone) 
supplemented with 100-200 mM ribitol instead 
of 100-200 mM glucose. Moreover, when 
adding 5 mM U-13C-ribitol to minimal medium 
containing 2% glucose, we could not detect any 
13C-labeled ribulose in cellular extracts prepared 
from the yeast cultivations, neither for the wild-
type nor for the ydr109cΔ strains. This suggests 
that, unlike for certain mammalian cell types and 
in agreement with previous observations (43), 
ribitol is not metabolized by S. cerevisiae cells.  
Pathogenic (e.g. Candida albicans) and 
osmotolerant (e.g. Zygosaccharomyces rouxii) 
yeast species are known to produce high 
amounts of D-arabitol (44,45). Based on studies 
using [2-14C]glucose, it was shown that C. 
albicans produces D-arabitol by 
dephosphorylating D-ribulose-5-P and then 
reducing D-ribulose by an NAD-dependent D-
arabitol 2-dehydrogenase (D-ribulose reductase; 
Ard1) (46). The latter enzyme was also purified 
and characterized from Candida tropicalis (47). 
Many of the D-arabitol-producing yeast species 
are also able to utilize this pentitol as the sole 
carbon source (45). The D-arabitol utilization 
pathway most likely involves oxidation of 
arabitol to D-ribulose by D-arabitol 2-
dehydrogenase and phosphorylation of D-
ribulose to the pentose phosphate pathway 
intermediate D-ribulose-5-P by the homolog of 
the D-ribulokinase protein identified in this 
study. Ydr109c is indeed well conserved in 
Candida as well as in osmotolerant 
Zygosaccharomyces species. S. cerevisiae does 
not produce D-arabitol (44) and it is unlikely 
that D-ribulokinase participates in D-arabitol 
utilization in this species. 
Why then, one may ask, has D-
ribulokinase been conserved in species such as 
baker’s yeast and higher eukaryotes, including 
humans? The most plausible endogenous 
precursor, in these species, for the D-
ribulokinase substrate is certainly D-ribulose-5-
P. We propose therefore that a possible 
physiological role of D-ribulokinase in species 
or cell types that do not produce significant 
amounts of free D-ribulose from pentitols or 
other pentose precursors, may be to preserve the 
D-ribulose-5-P pool or to prevent potentially 
toxic accumulations of free D-ribulose by ‘re-
phosphorylating’ D-ribulose formed by 
nonspecific phosphatase activities from D-
ribulose-5-P. As such, D-ribulokinase could be 
added to the growing list of so-called metabolite 
repair enzymes, i.e. enzymes that function to 
remove useless or sometimes toxic metabolites 
formed via side activities of metabolic enzymes 
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(48,49). In both S. cerevisiae and higher 
eukaryotes, low molecular weight phosphatases 
of the haloacid dehydrogenase protein 
superfamily may contribute to free ribulose 
formation from D-ribulose-5-P. Some of these 
phosphatases are quite promiscuous and in S. 
cerevisiae, the poorly characterized Ykr070w 
and Ynl010w haloacid dehalogenase 
phosphatases have recently been shown to 
hydrolyze D-ribulose-5-P in addition to a range 
of other phosphomonoesters tested (50). In 
earlier studies, a partially purified acid 
phosphatase preparation, but not alkaline 
phosphatase preparation, from Z. rouxii was 
shown to display ribulose-5-P phosphatase 
activity (51). The existence of such phosphatase 
activities in mammals is supported by the 
presence of free ribulose in the urine of humans 
and fasted rats (52) and of elevated pentitol 
levels measured in patients with inborn errors in 
the pentose phosphate pathway. In humans, 
ribitol is usually present at very low levels in 
extracellular fluids (less than 6 µM in plasma 
and CSF (53)), but this pentitol as well as D-
arabitol accumulate in patients with ribose-5-
phosphate isomerase (53) or transaldolase (54) 
deficiencies. In a patient with ribose-5-
phosphate isomerase deficiency, millimolar 
levels of ribitol and D-arabitol were measured in 
CSF (53). In these disorders, the amounts of free 
pentoses formed via hydrolysis of 
phosphopentose precursors thus seem to exceed 
the capacity of ribokinase and the herein 
identified D-ribulokinase, leading to the 
reduction of excess pentoses and their 
accumulation as pentitols. FGGY silencing did 
not lead to detectable ribulose levels in the 
human cell lines used in this study when 
cultivated without ribitol supplementation. This 
may be explained by the only partial knockdown 
achieved by the shRNA method used and/or low 
ribulose-5-P phosphatase activity in those cell 
lines.  
Alternatively, the simultaneous presence 
of D-ribulose-5-P phosphatase and D-
ribulokinase activities in a eukaryotic cell could 
in principle contribute to fine-tuning the 
regulation of the pentose phosphate pathway 
flux by substrate cycling (55) between ribulose-
5-P and ribulose. As opposed to the metabolite 
repair hypothesis, the participation of D-
ribulokinase in metabolic flux regulation 
through substrate cycling would, however, call 
for the existence of a specific and (for example 
allosterically) regulated ribulose-5-P 
phosphatase activity rather than a non-specific, 
non-regulated production of free ribulose by 
promiscuous phosphatases. 
While this work was ongoing, a new 
enzymatic activity producing CDP-ribitol was 
identified in mammals by three independent 
groups (56-58). This activity is carried by the 
ISPD protein, which acts as a CDP-ribitol 
pyrophosphorylase using ribitol-5-P and CTP to 
form CDP-ribitol. Furthermore, CDP-ribitol was 
shown to be used by the transferases FKTN and 
FKRP to incorporate ribitol-5-P from CDP-
ribitol into a phosphorylated O-mannosyl glycan 
(CoreM3) of the α-dystroglycan glycoprotein 
(57,58). Abnormal glycosylation of α-
dystroglycan, a receptor for matrix and synaptic 
proteins, can lead to congenital syndromes that 
are characterized by muscle, brain and/or eye 
disorders (59,60). Mutations in ISPD, FKTN, 
and FKRP had been known to cause 
dystroglycanopathies, but until these recent 
molecular identifications, their role in disease 
development had remained unknown. The 
metabolic pathway leading to the formation of 
ribitol-5-P, the substrate of ISPD, remains, 
however, unknown. Some of the bacterial 
homologs of ISPD are fused to a reductase that 
converts D-ribulose-5-P to ribitol-5-P (61). Such 
an activity would allow to produce CDP-ribitol 
from the pentose phosphate pathway 
intermediate D-ribulose-5-P without the need of 
a sugar kinase. In the mammalian system, the 
results obtained by Gerin et al. (58) indicate that, 
at physiological levels of ribitol, the pathway 
leading to ribitol-5-P formation involves a 
Sorbinil-sensitive aldose reductase and may 
indeed be independent of the FGGY protein 
studied here. However, at supraphysiological 
ribitol levels, the authors could show that FGGY 
silencing clearly leads to decreased CDP-ribitol 
formation in HEK293 cells. Under such 
conditions, FGGY is thus involved in CDP-
ribitol formation, either by directly 
phosphorylating ribitol or by phosphorylating D-
ribulose formed from ribitol. Our results show 
indeed that HEK293 cells can oxidize ribitol to 
D-ribulose and that the latter is a 35-fold better 
substrate for FGGY than ribitol in terms of 
catalytic efficiency. The observation that 
Sorbinil does not inhibit CDP-ribitol formation 
in HEK293 cells cultivated in the presence of 
externally added ribitol favors, however, the 
hypothesis of a direct phosphorylation of ribitol 
by FGGY under these conditions. Interestingly, 
ribitol supplementation in cultivation medium or 
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drinking water led to increased CDP-ribitol 
levels in mammalian cells and mice, 
respectively, and ribitol supplementation 
partially restored α-dystroglycan glycosylation 
in fibroblasts from patients with ISPD mutations 
(58). These observations suggest that in patients 
with mutations in ISPD, but also FKTN and 
FKRP, dietary ribitol supplementation could 
exert therapeutic effects via a pathway that 
depends on the ribitol and/or D-ribulose kinase 
activity of FGGY. 
 
EXPERIMENTAL PROCEDURES 
Chemicals–Unless otherwise indicated, 
chemicals were from Sigma Aldrich. All 
solvents used were HiPerSolv CHROMANORM 
LC-MS grade from VWR. Most of the analytical 
standards were either from Sigma Aldrich, 
Carbosynth or Roche and when possible were of 
greater than 90% purity; LC-MS grade 
chemicals were used when available. Cell 
culture media and supplements as well as trypsin 
were purchased from Life Technologies. The 
yeast minimal medium Yeast Nitrogen Base 
(YNB) with ammonium sulphate and peptone 
were from MP Biomedicals. Hygromycin B was 
purchased from Cayman Chemical Company.  
Microbial strains, cell lines, and 
plasmids–To reduce metabolic and physiological 
biases introduced by auxotrophic markers, 
prototrophic S. cerevisiae strains were used for 
the majority of yeast experiments shown in this 
study. To analyse the impact of two specific 
gene deletions on the metabolome, strains of the 
prototrophic deletion collection (MATa 
can1Δ::STE2pr-SpHIS5 his3Δ1 lyp1Δ0 ho-), 
created as described in (62), in which the 
YDR109C and MPA43 genes were replaced by 
the KanMX cassette were used. Those 
ydr109cΔ::KanMX and mpa43Δ::KanMX 
knockout strains are designated as ydr109cΔ and 
mpa43Δ strains throughout this article. As a 
wild-type control, we used an isogenic strain 
from the same deletion collection in which the 
non-functional HO allele was replaced by the 
KanMX cassette, except for co-cultivation 
experiments where an FY4 MATa prototrophic 
wild-type strain was used. For some 
experiments, auxotrophic BY4741 strains 
(MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) without 
or with deletion of the YDR109C gene by 
replacement with the KanMX cassette were used 
(Euroscarf).  
The BL21(DE3)pLysS E. coli cells used 
for recombinant protein expression were from 
Life Technologies. The stable HEK293 FGGY 
knockdown cell line and the corresponding 
control cell line were provided by Dr. Guido 
Bommer (58). The PH5CH8 cell line was 
provided by Dr. Nobuyuki Kato.  
The Gateway plasmid pDONR221, used 
to create Entry clones with attL sites upstream 
and downstream of the gene of interest, was 
from Invitrogen. The Gateway plasmid 
pDEST527 was a gift from Dominic Esposito 
(Addgene plasmid #11518). The empty Gateway 
plasmid p41Hyg 1-F GW was a gift from Leonid 
Kruglyak and Sebastian Treusch (Addgene 
plasmid # 58547) (63). 
Construction of plasmids for 
recombinant protein expression and rescue 
experiments–To express the yeast YDR109C 
gene in a bacterial system, the coding sequence 
was PCR-amplified from prototrophic wildtype 
S. cerevisiae FY4 (MATa) genomic DNA using 
the YDR109cFwd and YDR109cRev primers 
(Table S5) and high-fidelity Phusion DNA 
polymerase (Thermo Scientific). The primers 
were designed to contain attB sites and the 
Gateway Cloning strategy (Thermo Fisher 
Scientific) was followed according to the 
manufacturer’s instructions to clone the purified 
attB-flanked PCR product into the pDONR221 
Entry vector, and to subsequently subclone the 
insert into the pDEST527 Destination vector. 
This resulted in the pDEST527-YDR109C 
expression plasmid allowing for ITPG-inducible 
production of N-terminally 6x His-tagged fusion 
protein in E. coli. 
Similarly, to produce recombinant 
human FGGY protein, the coding sequence of 
the human FGGY gene was amplified from the 
cDNA IMAGE clone ID 4871664 (Source 
Bioscience) using the FGGYfwd and FGGYrev 
primers (Table S5). The PCR product was 
cloned into the pDONR221 vector and 
subcloned into the pDEST527 vector, as 
described above, to obtain the pDEST527-FGGY 
expression vector.  
A plasmid (p41Hyg 1-F GW-YDR109C) 
to rescue the yeast metabolic phenotype after 
YDR109C deletion was prepared by Gateway 
insertion of the YDR109C coding sequence as 
well as the 840 nucleotides upstream of the ATG 
start codon and 300 nucleotides downstream of 
the stop codon into the low copy number CEN 
vector p41Hyg 1-F GW(63). The YDR109C 
gene sequence was PCR-amplified from 
prototrophic wildtype S. cerevisiae FY4 (MATa) 
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genomic DNA using the YDR109cFwdres and 
YDR109cRevres primers (Table S5). 
All the recombinant vectors described 
above were confirmed by Sanger sequencing 
(Eurofins Scientific) to contain the expected 
insert sequences in the correct orientation. 
Yeast recombinant protein expression 
and purification–Chemically competent One 
Shot BL21(DE3)pLysS E. coli cells were 
transformed by heat shock with the pDEST527-
YDR109C plasmid according to the 
manufacturer’s instructions. Positive 
transformants were selected for on LB-agar 
plates containing 100 µg/ml ampicillin. A single 
positive transformant colony was cultured in LB 
containing 100 µg/ml ampicillin and 2% (w/v) 
D-glucose at 37 °C until OD600 reached 0.7. 
Recombinant His-Ydr109c expression was 
induced with the addition of 500 µM IPTG and 
cultures were grown for another 20 h at 37 °C. 
Cells were harvested by centrifugation at 4500 x 
g for 15 min at 4 °C and the cell pellet was 
stored at -80 °C until further processing.  
For protein extraction, cells were 
resuspendend in a lysis buffer (50 µl buffer per 1 
ml of original bacterial culture) containing 20 
mM HEPES at pH 7.4, 1 mM DTT, 0.5 mM 
PMSF, and 1x cOmplete EDTA-free protease 
inhibitor cocktail (Roche Applied Science) and 
sonicated on ice (Branson Digital sonifier 250; 5 
pulses of 0.5 s at an amplitude of 50% separated 
by 1 min breaks to minimize sample heat-up). 
The insoluble fraction was removed by 
centrifugation at 15,000 x g for 40 min at 4 °C 
and the supernatant was collected for a one-step 
purification and enzyme activity assays on the 
same day, given important activity losses 
observed in preliminary experiments upon 
additional purification steps and/or freeze-thaw 
cycles. 
The His-Ydr109c protein was purified 
using a 1 ml HisTrap HP column (GE 
Healthcare) on an ÄKTA protein purifier (GE 
Healthcare), keeping the temperature at 4 °C 
throughout the procedure. Before purification, 
the imidazole concentration in the protein extract 
was adjusted to 10 mM and the preparation was 
filtered on a surfactant-free cellulose acetate 
membrane (1.2 µm pore size, Sartorius). After 
equilibration of the HisTrap column with 20 ml 
buffer A (25 mM Tris-HCl, 300 mM NaCl, pH 
8) containing 10 mM imidazole, the protein 
filtrate was applied onto the column at a flow 
rate of 1 ml/min. Non-specifically bound 
proteins were removed by washing the column 
with 20 ml of 18.7 mM imidazole in buffer A. 
The His-tagged protein was eluted by applying a 
20-min linear imidazole gradient (18.7-300 mM) 
in buffer A, during which 1 ml fractions were 
collected and kept on ice. Pure fractions 
containing His-tagged protein at the expected 
MW were identified by SDS-PAGE and Western 
blot analysis using an anti-His antibody (mouse-
derived, 1:1500 dilution in PBS with 0.1% 
Tween 20 (v/v); GE Healthcare) and a 
fluorescent secondary antibody (IRDye 680RD, 
goat-derived, 1:10,000 dilution in Odyssey 
blocking buffer; Westburg, Leusden, 
Netherlands). 
Human recombinant protein expression 
and purification–The human recombinant N-
terminal 6x His-tagged FGGY protein was 
produced and purified similarly as the His-
Ydr109c protein, with slight modifications in the 
protocol. Protein expression was induced at an 
OD600 of 0.4 by addition of 200 µM IPTG and E. 
coli cells were harvested 18 h later. For the 
purification on the HisTrap HP column, a more 
shallow 20-min imidazole gradient (18.7 -184 
mM) was used. Unlike His-Ydr109c, the His-
FGGY protein was very stable. An additional 
desalting step was performed for the latter 
protein on a 5 ml Hi-Trap desalting column (GE 
Healthcare). 1 ml of active fraction eluted from 
the His-Trap HP affinity column was loaded and 
a buffer at pH 7.5 containing 20 mM Tris-HCl 
and 25 mM NaCl was applied at a flow rate of 
2.5 ml/min. The desalted purified His-FGGY 
protein fractions were stored at -80 °C.  
Sugar kinase activity assay–The kinase 
activities of the recombinant Ydr109c and 
FGGY proteins were determined using the 
PK/LDH assay system allowing the coupling of 
ADP formation by the kinase to NADH 
oxidation by LDH. The rate of NADH 
consumption, equivalent to the rate of sugar 
phosphorylation, was determined 
spectrophotometrically in a plate reader (Infinite 
M200 PRO, TECAN) or spectrophotometer 
(SPECORD 210 Plus, Analytik Jena) by 
monitoring the absorbance at 340 nm at 30 °C in 
a reaction mixture (total volume of 200 µl or 1 
ml for the plate reader and spectrophotometer, 
respectively) containing 25 mM HEPES pH 7.1, 
5 mM ATP-MgCl2, 0.16 mM NADH, 1 mM 
phosphoenol pyruvate, 8 U/ml of pyruvate 
kinase, 8 U/ml of L-LDH and the indicated 
concentrations of the sugars and sugar 
derivatives tested as substrates. The enzymatic 
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reaction was launched by addition of 
recombinant Ydr109c or FGGY protein, at a 
final concentration of 4.3 µg/ml and 1.9 µg/ml, 
respectively.  
Yeast cultivation, measurement of cell 
volume, and metabolite extraction–The S. 
cerevisiae WT and ydr109cΔ (or mpa43Δ) KO 
prototrophic strains were streaked onto YPD 
agar plates containing 200 µg/ml of Geneticin 
(G418). Single colonies were inoculated into 5 
ml YPD (2% glucose) for overnight pre-
cultivation at 30 ºC. Precultures were diluted 
100 times in 5 ml YNB supplemented with 2% 
glucose and incubated at 30 °C with shaking at 
200 rpm for 10 hours. The final cultivars were 
obtained by inoculating 25 ml YNB with 2% 
glucose, in a 250-ml flask, at an initial OD600 of 
0.01. A similar cultivation method was used for 
the auxotrophic strains except that the YNB 
medium was supplemented with 80 mg/L uracil, 
80 mg/L histidine, 80 mg/L methionine, and 240 
mg/L leucine. Cell number and cell volume were 
determined in aliquots taken from the yeast 
cultivations using a Multisizer 3 Coulter Counter 
equipped with a 30-µm measurement capillary 
(Beckman Coulter) after diluting the samples 
1:400 in ISOTON II solution (Prophac). 
Metabolites were extracted using a 
protocol adapted from (64), when the OD600 of 
the final cultivars was between 3.0-3.4. Two-ml 
aliquots of yeast cultivar were quenched by 
adding 8 ml of 60 % (v/v) methanol at -40 °C. 
After a 2-min incubation at -40 °C, the cells 
were separated from the quenching solution by 
centrifuging at 4400 x g at -10 °C for 5 min. 
Metabolites were extracted from the pellet by 
addition of 2 ml chloroform (-20 °C), 1 ml 
methanol (-80 °C) and 0.8 ml 10 mM 
ammonium acetate at pH 7.1 (4 °C), followed by 
45 min vortexing at -20 °C. The chloroform and 
aqueous phases were separated by centrifugation 
at 4400 x g at -10 °C for 10 min. 1 ml of the 
upper aqueous phase containing polar 
metabolites was dried under vacuum at -4 °C 
overnight and the dried samples were stored at -
80 °C. Before analysis, the samples were 
resuspended in 80 % (v/v) acetonitrile or Milli-Q 
water for ZIC-HILIC-MS/MS or reverse phase-
MS analysis, respectively, and filtered on 
regenerated cellulose membranes with 0.2 µm 
pore size (Phenomenex).  
Yeast RNA extraction and quantitative 
RT-PCR–To isolate yeast RNA, samples were 
obtained from cultivations produced in the same 
way as for metabolite extraction. Cells were 
harvested by centrifugation (5 min at 4500 x g 
and 4 °C) from 20 ml of cultures that had 
reached an OD600 of 3.0-3.4 and resuspended in 
800 µl of TriPure isolation reagent (Sigma 
Aldrich). The samples were incubated at room 
temperature for 10 min and then transferred to 2-
ml Precellys homogenizer tubes (Peqlab) along 
with 300 mg acid-washed glass beads (425-600 
mm diameter, Sigma Aldrich). The samples 
were homogenized in the Precellys for 30 s at 
6000 rpm and 5-10 °C. 200 µl of chloroform 
were added to the cell lysates and samples were 
shaken for 15 min at 1400 rpm and room 
temperature, followed by static incubation for 5 
min. Samples were centrifuged for 15 min at 
12000 x g and 4 °C. The aqueous supernatants 
were added to 500 µl of 4 °C isopropanol, 
followed by gentle mixing by inverting tubes 
and incubation at room temperature for 10 min. 
The samples were then centrifuged for 15 min at 
12000 x g and 4 °C and the RNA pellet was 
washed with 1 ml of 70% ethanol. After an 
additional 5-min centrifugation at 12000 x g and 
4 °C, the RNA pellets were dried, resuspended 
in 30 µl of RNase-free water and incubated at 55 °C for 10 min. Residual genomic DNA was 
removed from RNA samples by rigorous DNase 
treatment (TURBO DNase treatment kit, Life 
Technologies) following the manufacturer’s 
protocol. Complementary DNA was synthesized 
from ~ 0.5 µg DNAse treated RNA using the 
RevertAid H Minus First Strand cDNA 
Synthesis Kit and Oligo(dT)18 primers (Thermo 
Fisher Scientific), following the manufacturer’s 
instructions. The resulting cDNA samples were 
diluted 20 times in water and 2 µl of these 
dilutions were used in 20 µl qPCR reactions to 
determine the expression levels of the YDR109C 
gene. The qPCR primer sequences are given in 
Table S5; the ACT1 and ALG9 genes were used 
as house-keeping reference genes. qPCR 
reactions were run on a Lightcycler 480 
instrument (Roche) using the SYBR green 
supermix reagent (Bio-Rad) and 0.25 µM gene-
specific forward and reverse primers. The qPCR 
cycle settings were 95 °C for 5 min, then 45 
cycles at 95 ºC for 30 s, 60 ºC for 30 s, and 72 
ºC for 30 s with acquisition of fluorescence 
information followed by a melting curve. 
Yeast stable isotope labeling 
experiments and production of a U-13C labeled 
internal standard for ribulose quantification–A 
co-cultivation protocol for improved untargeted 
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LC-HRMS-based metabolomics analyses was 
adapted from (20). Three replicate cultures of 
each the MATa FY4 WT and the ydr109cΔ S. 
cerevisiae prototrophic strains were inoculated 
from single colonies on YPD plates into 5 ml 
YNB supplemented with 2% (w/v) non-labeled 
glucose and incubated overnight at 30 °C with 
shaking. Aliquots of the overnight pre-cultures 
were diluted 100-fold into 5 ml YNB containing 
non-labelled glucose or U-13C-glucose as sole 
carbon source at a concentration of 2% and 
incubated for 9 hours at 30 °C with shaking. 
Main cultures were launched by inoculating 25 
ml YNB containing 2% non-labeled glucose or 
U-13C-glucose at a starting OD600 of 0.01. For 
each strain, three non-labeled culture replicates 
and one labeled culture replicate were prepared. 
Polar metabolites were extracted using the 
method described above from each of the culture 
replicates. The 13C-labeled WT and ydr109cΔ 
extracts were mixed in a 1:1 ratio. This pooled 
labelled extract was then spiked as an internal 
standard into the individual non-labeled extracts 
in a 1:1 ratio for subsequent ZIC-HILIC-ddMS2 
measurements and data analysis by an extended 
version of the MetExtract software (20,21). The 
pooled 13C-labeled extract was also used for 
estimation of the intracellular concentration of 
D-ribulose in selected WT and KO metabolite 
extracts by spiking this internal standard into the 
samples and into non-labeled D-ribulose 
standard solutions in a 1:1 ratio. Spiked samples 
(1 ml) were dried under vacuum at -4 °C 
overnight and stored at -80 °C until further use. 
Before ZIC-HILIC-ddMS2 analysis, dried 
samples were reconstituted as described above. 
In addition, the 13C-labeled ydr109cΔ 
extract prepared as described above was used to 
further confirm the identity of the pentose peak 
accumulating in the knockout strain by mixing 
the labeled extract in a 1:1 ratio with non-labeled 
D-ribulose, D-ribose or D-xylulose standards (all 
at an initial concentration of 100 µM) directly 
followed by ZIC-HILIC-ddMS2 analysis. 
Cell culture and knockdown of FGGY in 
human HEK293 and PH5CH8 cells–HEK293 
cells stably transduced with shRNA expression 
constructs and PH5CH8 cells were cultured in 
DMEM medium (Life Technologies) containing 
4.5 g/L glucose, 1 mM pyruvate, and 10% fetal 
bovine serum. The HEK293 cultivation medium 
was additionally supplemented with 1% 
Penicillin/Streptomycin (Life Technologies), 1 
µg/ml puromycin (InvivoGen), and 2 mM 
GlutaMax (Life Technologies). The cell lines 
were incubated at 37 °C in an atmosphere of 5% 
CO2 in air.  
The stable HEK293 cell line with 
doxycycline-inducible expression of an FGGY-
specific shRNA and a corresponding control cell 
line were created using a lentiviral transduction 
strategy based on the pTRIPZ plasmid and 
selection using puromycin as described in (58). 
In this study, we used the FGGY knockdown cell 
line obtained with the pIG271 plasmid, which 
was constructed by inserting a PCR-amplified 
oligonucleotide pair into the empty pTRIPZ 
plasmid, starting from the following sequences: 
hFGGY1_s 5’-TGC TGT TGA CAG TGA GCG 
ACA TCG AGC AGT CAG TCA AGT TTA 
GTG AAG CCA CAG ATG TA-3’ and 
hFGGY1_as 5’-TCC GAG GCA GTA GGC 
ACC ATC GAG CAG TCA GTC AAG TTT 
ACA TCT GTG GCT TCA CTA-3’ (58). About 
100,000 cells (in 1 ml medium) were initially 
seeded per well into 12-well plates (Nunc). 
Expression of shRNA was induced by 
supplementing media with 1 µg/ml doxycycline 
after 16 h of incubation and various ribulose 
precursors were added to the media at the same 
time. Metabolites and RNA were extracted from 
different replicate wells 41 hours later.  
In the PH5CH8 cell line, transient 
knockdown of FGGY was achieved by 
transfection of a gene-specific siRNA pool (ON-
TARGETplus SMARTpool from Dharmacon) 
using Lipofectamine 2000 (Life Technologies). 
In parallel, control cells were transfected in the 
same way with non-targeting siRNAs (ON-
TARGETplus non-targeting pool from 
Dharmacon). About 100,000 cells (in 2 ml 
medium) were seeded per well into 6-well plates 
(Nunc). Cells were transfected the following day 
using 30 nM siRNA and 6 µl of transfection 
reagent in the absence of antibiotics in the Opti-
MEM culture medium according to the 
manufacturer’s instructions. The culture medium 
was replaced by fresh DMEM medium 
containing various ribulose precursor candidates 
at the indicated concentrations about 8 h after 
addition of the RNA-Lipofectamine 2000 
complexes. After 24 h, a second round of siRNA 
transfection followed by medium exchange was 
performed as described above. Metabolites and 
RNA were extracted from different replicate 
wells 48 h later. 
Metabolite and RNA extraction from 
human cells and quantitative RT-PCR–To 
extract metabolites from human cells cultivated 
in 6-well plates, the media was removed and the 
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cells were washed with 1 ml of 0.9 % (w/v) 
NaCl. To the washed cells, 400 µl of -20 °C 
methanol and 400 µl cold milliQ water were 
added, cells were detached using a cell scraper, 
keeping the plates on ice, and the cell lysate was 
collected into 2 ml tubes on ice. To the cell 
lysate, 400 µl of -20 ºC chloroform were added 
and the mixture was vortexed for 20 min at 1400 
rpm and 4 °C, followed by a 5-min 
centrifugation at 15000 x g and 4 ºC. 300 µl of 
the upper aqueous phase, containing polar 
metabolites, were dried under vacuum at -4 °C 
and the dried samples were stored at -80 ºC until 
metabolite analysis. For cells cultivated in 12-
well plates, the volume of the reagents added for 
metabolite extraction was halved.  
To extract RNA from the HEK293 and 
PH5CH8 cells, media was removed and the cells 
were resuspended in 1 ml of TriPure Isolation 
Reagent (Sigma Aldrich). Total RNA was 
isolated from the TriPure cell extracts after 
phase separation using chloroform according to 
the manufacturer’s instructions. The RNA 
concentration was determined by measuring the 
absorbance at 260 nm and the samples were used 
directly for cDNA synthesis or stored at -80 °C.  
To measure FGGY transcript levels in HEK293 
and PH5CH8 knockdown cells, cDNA synthesis 
and qPCR reactions were performed as 
described above for measuring gene expression 
in yeast cells, except that 1.8 µg RNA was 
engaged in the cDNA synthesis reactions and 
that reverse transcription reactions were diluted 
10-fold before addition to the qPCR reaction 
mixture. The sequences of the qPCR primers 
used for the FGGY gene as well as for the ACTB 
and GAPDH reference genes are given in Table 
S5. 
LC-MS and LC-MS/MS methods–
Metabolites were analysed using a Dionex 
UltiMate 3000 LC system coupled to a Q 
Exactive Orbitrap mass spectrometer (Thermo 
Fisher Scientific). Nitrogen was supplied by a 
Genius 1022 high purity generator (Peak 
Scientific Instruments, Ltd.). Chromatographic 
separation was performed using either a SeQuant 
ZIC-HILIC column (150 x 2.1 mm, 3.5 µm, 100 
Å; Merck) fitted with a SeQuant ZIC-HILIC 
guard column (14 x 1 mm, 5 µm, 200 Å; Merck) 
or an Acquity UPLC HSS T3 column (150 x 2.1 
mm, 1.8 µm, 100 Å; Waters) fitted with a 
VanGuard Acquity UPLC HSS T3 guard column 
(5 x 2.1 mm, 1.8 µm, 100 Å; Waters). The LC 
method for separation of metabolites using the 
ZIC-HILIC column was adapted from (65) with 
the solvent flow modified to a constant flow rate 
of 150 µl/min and column re-equilibration time 
increased to 10 min. Briefly, using buffers A 
(0.1% formic acid in water) and B (0.08% 
formic acid in acetonitrile), the solvent gradient 
was 80% B to 20% B from 0-30 min, 20% B to 
5% B from 30-31 min, an isocratic step at 5% B 
from 31-39 min to wash the column, 5% B to 80 
% B from 39-40 min, and another isocratic step 
at 80% B from 40-50 min to re-equilibrate the 
column. The column oven was set to 20 ºC. For 
the LC-MS method involving RP 
chromatography on the Acquity HSS T3 
column, the same buffers A and B were used. 
The column oven and solvent flow rate were set 
to 40 ºC and 350 µl/min, respectively. For each 
run, the column was equilibrated with 1% buffer 
B from 0-1 min, followed by a gradient of 1% B 
to 90% B from 1-30 min, an isocratic step at 
90% B from 30-32 min, a decrease from 90% B 
to 1% B from 32-33 min, and another isocratic 
step at 1% B from 33-35 min to re-equilibrate 
the column.  
For non-targeted metabolomics, mass 
spectrometry detection was done either in full 
scan mode with negative and positive 
electrospray ionization switching or using a 
ddMS2 method in either negative or positive 
ionization mode. For the ZIC-HILIC-ddMS2 
method, the following settings were used for the 
heated electrospray ionization (HESI-2) in both 
the positive and negative modes: sheath gas flow 
rate of 40, auxiliary gas flow rate of 10, sweep 
gas flow rate of 2, capillary temperature of 250 °C, S-lens RF level of 50, and auxiliary gas 
heater temperature of 300 °C. The spray current 
was set to 2.5 kV in negative mode and 3.5 kV 
in positive mode. The HESI-2 probe settings 
used with the reverse-phase full scan method in 
negative ionization mode were the same as for 
the ZIC-HILIC-ddMS2 method, whereas for the 
reverse-phase full scan method in positive 
ionization mode the settings were the following: 
sheath gas, auxiliary gas, and sweep gas flow 
rates set to 49, 12, and 2, respectively, spray 
voltage of 3.5 kV, capillary temperature of 259 °C, S-lens RF level of 50, and auxiliary gas 
heater temperature of 300 °C. Full scan MS with 
pos/neg switching was done with a mass 
resolution of 70,000, an automatic gain control 
set to 3 x 106, a maximal injection time of 200 
ms, and a m/z scan range of 70-1050. For 
ddMS2 experiments, a survey full scan with 
these same parameters was run and MS2 data 
was recorded for the top 7 m/z features with the 
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highest abundance in the survey scan. The 
parameters for MS2 recording were a mass 
resolution of 17,500, an automatic gain control 
set to 105, a maximal injection time of 50 ms, a 
parent ion isolation width of 2 m/z, a normalized 
collision energy of 40% to fragment the parent 
ion, a trigger function underfill ratio of 1% with 
isotope exclusion for MS2 trigger, and a 
dynamic exclusion of 10 s to minimize 
redundant MS2 acquisitions.  
A targeted ZIC-HILIC-MS method with 
SIM was used to measure ribulose in human cell 
extracts. In this method, the quadrupole scanning 
range was restricted to m/z 149-150. All other 
parameters were the same as for the ZIC-HILIC-
ddMS2 method.  
MS file conversions and data analysis–
Files with .raw format were converted to the 
mzXML format using the ‘MSconvert’ package 
of the ‘ProteoWizard’ software, using ‘R’. For 
data acquired with the ddMS2 method, MS1 
scan events were separated from MS2 scan 
events. The MZmine-2.20 software (66) was 
used for untargeted metabolite profiling data 
analysis. All parameter settings used for the 
various modules of MZmine 2.20 are given in 
the supplemental experimental procedure 
section. For the co-cultivation experiments, 
additional data analyses were performed using 
the MetExtract software (21). For targeted 
analyses, chromatographic peak areas of interest 
were integrated with the Qual browser utility in 
Xcalibur (Thermo Scientific).  
Statistical analysis–The statistical 
analyses of peak height data tables obtained 
from the MZmine 2.20 analysis were performed 
with the MetaboAnalyst 3.0 online tool (67). All 
the peaks having any match in KEGG, adduct 
search match and/or an in-house metabolite 
library match (within 10 ppm difference in m/z) 
were retained and the heights of all the 
individual peaks retained for each sample were 
normalized to the sum of all the retained peak 
heights for this sample (also referred to as 
metabolic TIC or mTIC normalized data). 
Univariate Welch’s t-test, multivariate Principal 
Component Analysis (PCA) and multivariate 
Partial Least Squares-Discriminant Analysis 
(PLS-DA) were performed on the mTIC 
normalized data. The PLS-DA model was 
evaluated by using leave-one-out cross 
validation. Higher values of the R2 statistic 
indicated that the PLS-DA model was well 
fitted. Higher values of the Q2 statistic indicated 
that the model was not overfitted. 
Multiple sequence alignments, 
phylogenetic analysis, and prediction of 
specificity determining positions–Multiple 
sequence alignments were generated with the 
MUSCLE software tool (3.8 online version) (68) 
using default settings, except if otherwise 
indicated. To build a phylogenetic tree for 
FGGY protein family members, we used the 
(CARS) of 446 FGGY protein sequences 
assembled by Zhang et al.(3), which we 
extended by a set of 11 additional sequences that 
we confidently identified as D-ribulokinases 
based on our own experimental data, sequence 
conservation, and/or genome context (UniProt 
entries A6TBJ4, B6XGJ3, M9RKB9, B9K586, 
I2IVR0, Q04585, Q96C11, A2AJL3, Q6NUW9, 
Q9VZJ8 and F4JQ90). The CARS reference set 
of sequences from (3) was built upon 31 FGGY 
kinase sequences (28 from bacteria and 3 from 
eukaryotes) with experimentally assigned 
molecular and biological functions. It was then 
expanded to 446 kinase sequences by 
propagation to bacterial homologs with at least 
30% sequence identity to one of the 31 starting 
sequences as well as a conserved genomic and 
pathway context supporting their functional 
assignments (3). Within the CARS dataset, 25 
clusters with more than 30% sequence identity 
can be distinguished covering a total of nine 
different substrate specificities, i.e. functions. 
Some isofunctional groups (e.g. glycerol kinases 
and L-ribulose kinases) thus span multiple 
sequence similarity clusters. The D-ribulokinase 
cluster of the original CARS protein set 
contained 7 sequences (Uniprot ID O52716 and 
SEED_PEGids fig|272943.3.peg.3604, 
fig|204722.1.peg.2375, fig|216596.1.peg.7085, 
fig|224911.1.peg.3226, fig|288000.5.peg.1100, 
fig|224914.1.peg.3039). The MSA generated 
based on the extended CARS sequence set 
(enriched in D-ribulokinase sequences) was used 
to perform a phylogenetic analysis with the 
FastTree 2.1.9 program (69) using a maximum-
likelihood model (Jones-Taylor-Thornton, 1992 
+ CAT) (70) and default settings. As in (3), the 
endonuclease subunit of exinuclease ABC 
(UvrC) was used as an outgroup to determine the 
root of the phylogenetic tree. 
Another MSA was generated to identify 
SDPs in the D-ribulokinase family of protein 
sequences. For this MSA, only the sequences 
contained in the largest cluster for each 
isofunctional group within the CARS protein set 
(Clust_IDs 48, 137, 11, 25, 124, 22, 85, 252 and 
13 from (3)) as well as the 11 additional D-
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ribulokinase sequences confidently annotated by 
ourselves added to the D-ribulokinase cluster 
(Clust_ID 25) were used (total of 337 
sequences). SDP prediction was performed using 
the GroupSim+Coswin method (30). The MSA 
prepared with MUSCLE was re-formatted 
manually to match the input format used by the 
GroupSim+Coswin software (grouping of the 
sequences according to their function and for 
each sequence, addition of the group name as 
suffix to the protein name).  
Based on (a) an MSA generated from D-
ribulokinase sequences from evolutionary distant 
organisms, (b) the SDPs predicted for the D-
ribulokinase family of proteins, and (c) 
structural information obtained from D-
ribulokinase homology models generated in this 
study, we defined a motif (TCSLV) that 
specifically characterizes the D-ribulokinase 
group of the FGGY protein superfamily. This 
motif was validated using the MSA generated as 
described above for the phylogenetic analyses 
and using an additional MSA generated with the 
Clustal Omega tool (default settings) (71) from 
about 634 reviewed FGGY family members 
retrieved from UniProt. The latter protein 
sequence set contained 10 isofunctional groups, 
including the 9 groups represented in the CARS 
protein set (kinases acting on D-glycerol, L-
ribulose, D-ribulose, L-rhamnulose, D-
gluconate, L-fuculose, D-xylulose, L-xylulose, 
and erythritol), but also a group of 
sedoheptulokinases in addition.  
Generation and analysis of structural 
homology models–For the FGGY (Homo 
sapiens) and Ydr109c (S. cerevisiae) proteins, 
no dedicated crystal structures were publicly 
available at the time of writing of this 
manuscript. Therefore, homology models for 
structural analysis were created using crystal 
structures for an ortholog from Yersinia 
pseudotuberculosis (UniProt Q665C6; sequence 
identity 51% to FGGY and 39% to Ydr109c; for 
the modelling, PDB structures 3L0Q, chain A, 
and 3GG4, chain A, were used). These structures 
were favoured as templates over an L-
ribulokinase crystal structure from Bacillus 
halodurans (PDB: 3QDK), since this L-
ribulokinase has a lower sequence identity to 
both human FGGY (27%) and yeast Ydr109c 
(24%), and a less well-resolved crystal structure 
(resolution of 2.31 Å as compared to 1.61 Å for 
3L0Q and 2 Å for 3GG4). 
To derive structural models from the 
chosen template protein, multiple candidate 
homology models were first generated and the 
best model for each protein was then determined 
using the quality assessment score of the 
software VERIFY3D (72). Specifically, the 
candidate models were obtained using I-
TASSER (73), SWISS-MODEL (74), RaptorX 
(75) and ModBase (76) (default parameters were 
used for all software tools). For both the FGGY 
and Ydr109c proteins, the homology model 
derived from ModBase provided the highest 
VERIFY3D score and was chosen for further 
analyses. 
Structural visualizations of the selected 
homology models, including the estimation of 
hydrogen bond and van-der-Waals interactions 
in the binding pocket, were generated with the 
software Chimera (77). Since the ligand D-
xylulose was included in the template crystal 
structure for FGGY (PDB: 3L0Q), but not in the 
template providing the best scored structural 
model for Ydr109c (PDB: 3GG4), molecular 
docking simulations with this ligand were 
performed in the Ydr109c structure using the 
software LeadIT/FlexX (version 2.1.5) (78). The 
top 30 docking poses were then determined and 
binding affinity estimates calculated for each 
pose by applying the LeadIT/HYDE tool (79). 
More details on the used docking pipeline can be 
found in (80). Finally, structural visualizations 
for the docking pose with the lowest estimated 
binding affinity were created using Chimera 
(77). 
Taxonomic distribution of D-
ribulokinase and L-ribulokinases–To analyze the 
taxonomic distribution of D-ribulokinase and L-
ribulokinases, we downloaded the FGGY_N 
domain sequences from the Pfam database for 
all the phyla possessing at least three such 
sequences (Archaea: crenarchaeota and 
euryarchaeota; Bacteria: acidobacteria, 
actinobacteria, armatimonadetes, bacteroidetes, 
chlorobi, chloroflexi, cyanobacteria, 
deinococcus thermus, dictyoglomi, firmicutes, 
fusobacteria, planctomycetes, α-proteobacteria, 
β-proteobacteria, ϒ-proteobacteria, δ-
proteobacteria, ε-proteobacteria, spirochaetes, 
synergistetes, tenericutes, thermotogae, 
verrucomicrobia; Eukaryota: alveolata, 
amoebozoa, chanoglagellida, euglenozoa, fungi, 
haptophyceae, metazoa, parabasalia, 
stramenopiles, viridiplantae). The D-
ribulokinase and L-ribulokinase motifs defined 
in this study (TCSLV and TGTST, TSST, 
TGSSP, TGSTP, MMHGY, and TACTM, 
respectively) were used to estimate, for each 
 by guest on D
ecem
ber 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
D-Ribulokinase in yeast and mammals	
22	
	
phylum, the proportion of D- and L-
ribulokinases compared to all the proteins 
containing an FGGY_N domain in this phylum.
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1The abbreviations used are: CARS, confidently annotated reference set; CI, confidence interval; CSF, 
cerebrospinal fluid; Ct, cycle threshold; FKRP, fukutin-related protein; FKTN, fukutin; HRMS, high-
resolution mass spectrometry; IPTG, isopropyl β-D-1-thiogalactopyranoside; ISPD, isoprenoid 
synthase domain-containing protein; KEGG, Kyoto encyclopedia of genes and genomes; LC, liquid 
chromatography; MS, mass spectrometry; MS2, mass spectrometry-mass spectrometry; mTIC, 
metabolic total ion chromatogram; MW, molecular weight; PC, principal component; PCA, principal 
component analysis; PK/LDH, pyruvate kinase/lactate dehydrogenase; PLS-DA, partial least squares 
discriminant analysis; RP, reverse-phase; S-ALS, sporadic amyotrophic lateral sclerosis; SD, standard 
deviation; SDP, specificity determining positions; SGD, Saccharomyces genome database; SIM, 
selected ion monitoring; SIL, stable isotope labeling; UPLC, ultra performance liquid 
chromatography; VIP, variable importance in projection; YMDB, yeast metabolome database; ZIC-
HILIC-ddMS2, zwitterionic-hydrophilic interaction liquid chromatography-data dependent mass 
spectrometry mass spectrometry.  
 
FIGURE LEGENDS 
 
FIGURE 1. Expression levels of the YDR109C gene in the prototrophic yeast strains used in this 
study. Total RNA was extracted from exponentially growing cells of the WT and ydr109cΔ strains as 
well as the ydr109cΔ strain transformed with the p41Hyg 1-F::YDR109C plasmid (rescue) or the 
corresponding empty plasmid. The expression -fold change of the YDR109C gene in the indicated 
strains relative to the WT strain was calculated using the 2-ΔΔCt method. The expression level of the 
YDR109C gene in each sample was either normalized to reference gene ACT1 or ALG9. Means and 
standard deviations of three biological replicates are shown. 
 
FIGURE 2. Ribulose accumulates in an S. cerevisiae ydr109cΔ strain. (A) Extracted ion 
chromatograms (m/z 149.0445) obtained after ZIC-HILIC-MS analysis of ydr109cΔ and wild-type 
metabolite extracts as well as a D-ribulose analytical standard. (B) Head-to-tail comparison of the 
MS2 fragmentation pattern of the parent ion m/z 149.0445 detected in the ydr109cΔ extract at 
retention time 4.77 min and the D-ribulose standard. (C) Extracted ion chromatograms (m/z 
149.0445) of pentose and pentulose analytical standards analyzed by ZIC-HILIC-MS. The D and L 
forms of the sugars were not separable using ZIC-HILIC chromatography; all other isomers were 
separable at peak maxima. (D) Overlay of extracted ion chromatograms (m/z 149.0445 in red and m/z 
154.0612 in black) obtained after ZIC-HILIC-MS analysis of a ydr109cΔ metabolite extract generated 
from cells cultivated in the presence of U-13C-D-glucose as the sole carbon source and spiked with 
non-labeled D-ribulose, D-ribose, or D-xylulose standards. 
 
FIGURE 3. Multivariate statistics analyses of the metabolite profiles obtained for the wild-type 
and ydr109cΔ prototrophic stains using ZIC-HILIC-MS. In the score plots shown, the green and 
red oval shapes represent the 95% confidence intervals for the wild-type (WT; green ‘+’ symbols) and 
ydr109cΔ (KO; red ‘Δ’ symbols) replicates, respectively. (A) Principal component analysis (PCA) 
score plot showing principal component 1 (PC1) vs. PC2 for the negative mode mTIC normalized 
data. (B) PCA score plot for the positive mode mTIC normalized data. (C) Partial least squares 
discriminant analysis (PLS-DA) score plot showing component 1 vs. component 2 for the negative 
mode mTIC normalized data. Leave-one-out cross-validation statistics were R2 = 0.99 and Q2 = 0.98 
for component 1, and R2 = 1.00 and Q2 = 0.99 for component 2. (D) PLS-DA score plot for the 
positive mode mTIC normalized data. Leave-one-out cross-validation statistics were R2 = 0.98 and Q2 
= 0.96 for component 1 and R2 = 0.99 and Q2 = 0.96 for component 2. 
 
FIGURE 4. Ribulose accumulates in FGGY knockdown human cells exposed to ribitol. HEK293 
FGGY knockdown (KD) and control cells were cultivated in DMEM medium supplemented with 10 
mM ribitol. Metabolites and total RNA were extracted 41 h after addition of ribitol and pentoses were 
measured using a targeted ZIC-HILIC-MS method. (A) The FGGY knockdown efficiency was 
evaluated using quantitative RT-PCR. The relative expression level of FGGY was estimated using the 
2-ΔΔCt method. The expression level of the FGGY gene in each sample was either normalized to 
reference gene ACTB or GAPDH. Means and standard deviations of 12 (FGGY KD cells) and 11 
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(control cells) biological replicates are shown. (B) Box-and-whisker plot representing the area of the 
ribulose peak (EIC m/z 149.0445, [M-H]- ion in the negative mode). Statistical analysis by Welch’s t-
test confirmed that the mean ribulose peak area was significantly increased in the FGGY KD cells 
compared to the control cells (p-value = 0.0005; 6 biological replicates for each cell line). KD, 
Knockdown.  
 
FIGURE 5. SDS-PAGE and Western blot analyses of recombinant His-Ydr109c and His-FGGY 
proteins. The indicated purified His-Ydr109c (A, B) and His-FGGY (C, D) fractions were analysed 
by SDS-PAGE followed by Coomassie Blue staining and Western blotting using an antibody directed 
against the N-terminal polyhistidine tag fused to each of the recombinant proteins. Fractions eluted 
from an Ni2+ affinity column were analysed either before (His-Ydr109c) or after desalting (His-
FGGY). The expected molecular weight of the His-Ydr109c and His-FGGY proteins is 82.8 kDa and 
63.7 kDa, respectively. MW, Molecular Weight.  
 
FIGURE 6. Confirmation of the product of the reaction catalysed by human FGGY as ribulose-
5-phosphate. (A) A reaction mixture resulting from the PK/LDH coupled D-ribulokinase assay was 
analysed using ZIC-HILIC-ddMS2. The extracted ion chromatogram (m/z 229.0108, negative 
ionization mode) shows a peak at retention time 7.92 min that co-elutes with the external analytical 
standard D-ribulose-5-phosphate. (B) Head-to-tail comparison of the MS2 fragmentation pattern of 
the parent ion m/z 229.0108 eluting at 7.92 min during analysis of the enzyme assay mixture and of 
the co-eluting ion from the external D-ribulose-5-phosphate standard. 
 
FIGURE 7. Multiple sequence alignment of D-ribulokinase proteins across different kingdoms 
of life. Conserved amino acids are highlighted in different shades of blue according to the degree of 
conservation (the darker the shading the higher the conservation). The top 20 specificity determining 
positions (SDPs) are highlighted in red. The number above the SDPs indicates the ranking based on 
the scores calculated by the GroupSim+Conswin software (number 1 corresponds to the SDP with the 
highest score). Amino acids predicted to interact with the pentose substrate based on structural 
homology models of the yeast Ydr109c and human FGGY proteins are highlighted in yellow. The 
Uniprot identifiers of the protein sequences shown are A6TBJ4 (Klebsiella pneumoniae), B6XGJ3 
(Providencia alcalifaciens), M9RKB9 (Octadecabacter arcticus), B9K586 (Agrobacterium vitis), 
I2IVR0 (Burkholderia sp. Ch1-1), P53583 (Mpa43, Saccharomyces cerevisiae), Q04585 (Ydr109c, 
Saccharomyces cerevisiae), Q96C11 (Homo sapiens), A2AJL3 (Mus musculus), Q6NUW9 (Danio 
rerio), Q9VZJ8 (Drosophila melanogaster), and F4JQ90 (Arabidopsis thaliana). Note that the 
alignment includes the yeast Mpa43 protein, which, unlike the other proteins shown, most likely does 
not act as a D-ribulokinase. Accordingly, the D-ribulokinase signature motif defined in this study 
(TCSLV sequence highlighted by the box frame) is not strictly conserved in the MPA43 protein. 
 
FIGURE 8. Structural homology models of yeast Ydr109c and human FGGY proteins. (A) 
Homology models of the Ydr109c protein (A) and the FGGY protein (B) created using template 
structures from PDB entries 3LGG4 chain A and 3L0Q chain A, respectively, of Yersinia 
pseudotuberculosis D-ribulokinase. Residues corresponding to the top 20 specificity determining 
positions (SDPs) predicted in this study are highlighted in red. (C) Homology model of the FGGY 
protein in complex with the ligand D-xylulose (light green colour). The FGGY_C and FGGY_N 
domains are highlighted in dark blue and pink, respectively.  
 
FIGURE 9. Phyletic spread of D-ribulokinase and L-ribulokinases. The taxonomic distribution of 
D- and L-ribulokinase proteins was determined using the FGGY_N domain sequences present in the 
Pfam database at the time of analysis and the D-ribulokinase and L-ribulokinase motifs defined in this 
study (TCSLV and TGTST, TSST, TGSSP, TGSTP, MMHGY and TACTM, respectively). 
Eukaryotic, bacterial, and archaeal phyla are represented on blue, pink, and green backgrounds, 
respectively.  
 
FIGURE 10. Known and putative routes involved in D-ribulose metabolism. Overview of 
reactions and pathways leading to the production or utilization of D-ribulose. Some of the pathways 
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shown are only known to occur in certain microorganisms, as detailed in the main text. Dotted arrows 
represent hypothetical reactions for which no corresponding gene has been identified yet in any 
organism. The D-ribulokinase enzyme, for which the eukaryotic gene has been identified in this study, 
is highlighted.   
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TABLE 1. Substrate specificity of the carbohydrate kinase activity of Ydr109c and FGGY. The 
kinase activities of the recombinant purified His-Ydr109c and His-FGGY proteins were measured 
spectrophotometrically using the PK/LDH assay with 19 different sugars or sugar derivatives (all at a 
concentration of 1 mM). Enzymatic activities were corrected by control assays run in the absence of 
carbohydrate substrate. The results shown are mean relative activities ± SDs resulting from three 
replicative measurements. ND, not detected; SD, standard deviation.  
Substrate FGGY activity 
(%) 
Ydr109c activity  
(%) 
D-Ribulose 100 ± 2 100 ± 3 
L-Ribulose 8 ± 1 ND 
Ribitol 21 ± 1 ND 
D-Xylulose 1 ± 0.3 ND 
L-Xylulose 1 ± 0.3 ND 
D-Glucose ND ND 
Arabitol ND ND 
Erythritol ND ND 
L-Arabinose ND ND 
D-Arabinose ND ND 
D-Ribose 1 ± 0.3 ND 
Glycerol ND ND 
D-Ribulose-5-phosphate ND ND 
Gluconate ND ND 
2-Deoxy-D-ribose ND ND 
D-Lyxose ND ND 
D-Ribose-5-phosphate ND ND 
D-Mannitol ND ND 
D-Ribose-1-phosphate ND ND 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURE 
Untargeted metabolomics data analysis using MZmine 2.20 
The .raw files generated with the ZIC-HILIC-ddMS2 method were converted into mzXML files 
containing only the MS1 scans. Those files were used for data analysis with MZmine 2.20 (1) using 
the following parameters: 
Mass detection Mass detector centroid, MS level 1, noise level 5E5. 
Chromatogram builder Min time span 0 min, Min height 5E5, m/z tolerance 0.005 m/z or < 10 ppm. 
Smoothing Filter width 5. 
Chromatogram deconvolution algorithm noise amplitude, minimum peak height 5E5, peak duration 
minimum 0-10 min, amplitude of noise 1E5.  
Isotope peak grouper m/z tolerance 0.002-20 ppm, retention time tolerance 0.1 min, maximum charge 
2, representative isotope most intense. 
Alignment Join aligner m/z tolerance 0.001 m/z or 20 ppm, weight for m/z 30, retention time 
tolerance 0.2 min, weight for RT 35, Require same charge state checked, compare isotope pattern 
checked. Isotope m/z tolerance 0.005 m/z or 50 ppm, minimum absolute intensity 5E5, minimum 
score 40%.  
Duplicate peak filter m/z tolerance 0.001 m/z or 20 ppm, RT tolerance 0.2 min.  
Gap filling Peak finder intensity tolerance 40%, m/z tolerance 0.01 m/z or 100 ppm, retention time 
tolerance 0.2 min, RT correction checked.  
Peak list row filter Minimum peaks in a row 3, Minimum peaks in an isotope pattern 1, peak duration 
0-1.5 min.  
 
Compound Identification  
Online database search KEGG Compound Database, ionization type [M-H]- or [M+H]+ depending 
on the mode, Number of results 1000, m/z tolerance 0.001 m/z or 10 ppm.    
In house library match The metabolites were searched against an in-house metabolite library 
containing retention time and m/z information for a selection of metabolite standards analysed by the 
ZIC-HILIC-MS method. m/z tolerance 0.001 or 10 ppm, RT tolerance 1 min. 
Adduct search  
Positive mode [M+ACN+H]+ 42.0338 m/z, [M+NH4]+ 18.0338 m/z.  
Negative mode [M-H2O-H]- 19.0184 m/z, [M+FA-H]- 44.9982 m/z, [M+Na-H]- 21.9825 m/z. 
m/z tolerance 0.001 or 5 ppm, maximum relative adduct peak height 25%.  
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SUPPLEMENTAL TABLES 
 
Supplemental Legends for Tables S1-S4 
 
Supplemental Table S1. Metabolite -fold changes in ydr109cΔ  vs. wild-type prototrophic yeast 
strains detected by ZIC-HILIC-ddMS2 in negative ionization mode. Metabolite ID: Arbitrary 
number given to each m/z feature by MZmine 2.20 software; -Fold change (KO/WT): ratio of average 
peak height of an identified m/z feature in ydr109cΔ (KO) vs. wild-type (WT) strain; p-value: the p-
value calculated using the Welch’s t-test; q-value (FDR): false discovery rate for multiple testing; 
m/z: mass over charge ratio; RT: retention time; Metabolite: metabolite identified based on exact 
match of the m/z with any of the compounds present in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) compound database with less than 10 ppm mass error or based on retention time 
match and m/z match with less than 10 ppm mass error with our in-house library; Identification: the 
database from which the metabolite matches in the ‘Metabolite’ column resulted from; YMDB match 
[M-H]- <10ppm: m/z match with compounds present in the yeast metabolome database (YMDB) for 
the [M-H]- ion in the negative mode with less than 10 ppm mass error; KEGG formula: molecular 
formula of the compound resulting from the KEGG compound database (or in-house library) search; 
Number of Carbons, co-cultivation: number of carbons determined for the the m/z feature based on 
the co-cultivation stable isotope labeling analysis; RT match with in-house library: * indicates that the 
retention time of the compound does not match with the retention time of the same compound in the 
in-house library and the values in brackets indicate the actual retention of the compound in the in-
house library. ‘Not available’ indicates that the metabolite is not present in the in-house library. 
‘Exact match’ indicates that the retention time of the metabolite perfectly matches with the retention 
time of the same compound in the in-house library; VIP score (component 1): scores resulting from 
the variable in projection analysis with the PLS-DA model. Note: KEGG compound and YMDB 
database matches are tentative metabolite identifications based only on exact mass of an m/z feature 
and therefore these identities should be interpreted with caution. The identifications resulting from in-
house library matches, based on both exact mass and retention time match with compounds of the in-
house library, can be trusted with more confidence.  
 
Supplemental Table S2. Metabolite -fold changes in ydr109cΔ vs. wild-type auxotrophic yeast 
strains detected by ZIC-HILIC-ddMS2 in negative ionization mode. Explanations clarifying the 
content of each column can be found in legend to Table S1. 
 
Supplemental Table S3. Metabolite -fold changes in ydr109cΔ vs. wild-type prototrophic yeast 
strains detected by ZIC-HILIC-ddMS2 in positive ionization mode. Explanations clarifying the 
content of each column can be found in legend to Table S1. 
 
Supplemental Table S4. Metabolite -fold changes in ydr109cΔ vs. wild-type auxotrophic yeast 
strains detected by ZIC-HILIC-ddMS2 in positive ionization mode. Explanations clarifying the 
content of each column can be found in legend to Table S1. 
 
Supplemental Tables S1-S4 
see Excel files ‘TableS1.xlsx’, ‘TableS2.xlsx’, ‘TableS3.xlsx’, and ‘TableS4.xlsx’ 
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Supplemental Table S5. List of all the primers used in this study 
 
Primer name Primer sequence 5’-3’ Purpose 
YDR109cFwd GGGGACAAGTTTGTACAAAA
AAGCAGGCTTCATGAAAAGC
AGGAAACGCC 
Gene cloning into 
pDONR221 (protein 
expression) 
YDR109cRev GGGGACCACTTTGTACAAGA
AAGCTGGGTCTTAATGGTGAT
GGTGATGGTGTCTACTAAAGG
ACCCTTCTACT 
Gene cloning into 
pDONR221 (protein 
expression) 
FGGYFwd GGGGACAAGTTTGTACAAAA
AAGCAGGCTTCGAAAACCTGT
ACTTCCAGGGTATGTCTGGTG
GAGAACAGAAACC 
Gene cloning into 
pDONR221 (protein 
expression) 
FGGYRev GGGGACCACTTTGTACAAGA
AAGCTGGGTCTCAGTCATCAT
TCATGATCGCC 
Gene cloning into 
pDONR221 (protein 
expression) 
YDR109cFwdres GGGGACCACTTTGTACAAGA
AAGCTGGGTTAACATTTCCTT
CATCATCA 
Gene cloning into 
pDONR221 (metabolic 
phenotype rescue) 
YDR109cRevres GGGGACAAGTTTGTACAAAA
AAGCAGGCTGTACCTATTCAG
AGATCAAA	
Gene cloning into 
pDONR221 (metabolic 
phenotype rescue) 
YDR109c_qPCR_fwd TCTACCAGTGGGTGTCGAAG qPCR experiment 
YDR109c_qPCR_rev ACGGGCTGATACATTCACCT qPCR experiment 
ACT1_fwd TCCCAGGTATTGCCGAAAGA qPCR experiment 
ACT1_rev CCACCAATCCAGACGGAGTA qPCR experiment 
ALG9_fwd CACGGATAGTGGCTTTGGTGA
ACAATTAC 
qPCR experiment 
ALG9_rev TATGATTATCTGGCAGCAGGA
AAGAACTTGGG 
qPCR experiment 
FGGY_qPCR_fwd TGGTCAGAGCGTTACTGGAA qPCR experiment 
FGGY_qPCR_rev TAAGGAAACCCACAGGCTGA qPCR experiment 
β-ACTfwd AGAAAATCTGGCACCACACC qPCR experiment 
β-ACTrev AGCACAGCCTGGATAGCAA qPCR experiment 
GAPDHfwd GCTCTCTGCTCCTCCTGTT qPCR experiment 
GAPDHrev GCGCCCAATACGACCAAAT qPCR experiment 
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SUPPLEMENTAL FIGURE 
 
Supplemental Figure S1. Phylogenetic tree based on a large sequence subset of the FGGY 
kinase protein family with high quality functional annotations, including prokaryotic and 
eukaryotic D-ribulokinases. The root of the tree was determined by using the endonuclease subunit 
of exinuclease ABC (UvrC) as an outgroup as in (2)	. More details on the phylogenetic analysis can be 
found in the Experimental Procedures section of the main text. The branches are colored according to 
the functional specifications. AraB, L-ribulokinase; EryA, erythritol kinase; FucK, L-fuculokinase; 
GntK, gluconokinase; GlpK, glycerol kinase; LyxK, L-xylulose kinase; RbtK, D-ribulokinase; RhaB, 
rhamnulokinase; XylB, xylulose kinase. 
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